WO2021068755A1 - 一类具有brd4抑制活性的化合物、其制备方法及用途 - Google Patents
一类具有brd4抑制活性的化合物、其制备方法及用途 Download PDFInfo
- Publication number
- WO2021068755A1 WO2021068755A1 PCT/CN2020/117478 CN2020117478W WO2021068755A1 WO 2021068755 A1 WO2021068755 A1 WO 2021068755A1 CN 2020117478 W CN2020117478 W CN 2020117478W WO 2021068755 A1 WO2021068755 A1 WO 2021068755A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- group
- alkyl
- mmol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 150
- 238000002360 preparation method Methods 0.000 title abstract description 37
- 230000002401 inhibitory effect Effects 0.000 title abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 102000001805 Bromodomains Human genes 0.000 claims abstract description 19
- 108050009021 Bromodomains Proteins 0.000 claims abstract description 17
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 123
- 125000001424 substituent group Chemical group 0.000 claims description 112
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 100
- -1 hydrate Substances 0.000 claims description 90
- 229910052757 nitrogen Inorganic materials 0.000 claims description 72
- 229910052736 halogen Inorganic materials 0.000 claims description 62
- 150000002367 halogens Chemical class 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 51
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 32
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 238000006467 substitution reaction Methods 0.000 claims description 25
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 23
- 150000002431 hydrogen Chemical class 0.000 claims description 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 125000004185 ester group Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 19
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 125000003368 amide group Chemical group 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 10
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 229940121649 protein inhibitor Drugs 0.000 claims description 3
- 239000012268 protein inhibitor Substances 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 108091005625 BRD4 Proteins 0.000 abstract description 21
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 abstract description 21
- 230000002265 prevention Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 566
- 239000000543 intermediate Substances 0.000 description 553
- 238000006243 chemical reaction Methods 0.000 description 377
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 276
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 270
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 217
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 213
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 204
- 238000003786 synthesis reaction Methods 0.000 description 192
- 230000015572 biosynthetic process Effects 0.000 description 189
- 235000019439 ethyl acetate Nutrition 0.000 description 189
- 239000007787 solid Substances 0.000 description 189
- 239000000243 solution Substances 0.000 description 172
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 163
- 238000004809 thin layer chromatography Methods 0.000 description 148
- 238000005160 1H NMR spectroscopy Methods 0.000 description 110
- 230000002829 reductive effect Effects 0.000 description 104
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 101
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 101
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 101
- 239000000047 product Substances 0.000 description 101
- 239000012074 organic phase Substances 0.000 description 98
- 239000000706 filtrate Substances 0.000 description 92
- 239000003208 petroleum Substances 0.000 description 79
- 238000003756 stirring Methods 0.000 description 67
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 53
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 52
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 51
- 239000012043 crude product Substances 0.000 description 48
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 43
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 39
- 238000004440 column chromatography Methods 0.000 description 39
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 36
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
- 239000012141 concentrate Substances 0.000 description 31
- 235000008504 concentrate Nutrition 0.000 description 31
- 238000012544 monitoring process Methods 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- 239000012065 filter cake Substances 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 238000001228 spectrum Methods 0.000 description 19
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 17
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 229910000029 sodium carbonate Inorganic materials 0.000 description 16
- FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 13
- 238000004808 supercritical fluid chromatography Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 12
- 229910000024 caesium carbonate Inorganic materials 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 239000005457 ice water Substances 0.000 description 12
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 11
- MPOYBFYHRQBZPM-UHFFFAOYSA-N 3h-pyridin-4-one Chemical compound O=C1CC=NC=C1 MPOYBFYHRQBZPM-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 235000019270 ammonium chloride Nutrition 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 11
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- ZIBFGMBXFNVTDE-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1C=2C(C(NC1)=O)=CNC2 Chemical compound C(C1=CC=CC=C1)C=1C=2C(C(NC1)=O)=CNC2 ZIBFGMBXFNVTDE-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000007791 liquid phase Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 9
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 7
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 7
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 7
- XFAWJIWICBTYDC-UHFFFAOYSA-N pyrrolo[2,3-c]pyridin-7-one Chemical compound O=C1N=CC=C2C=CN=C12 XFAWJIWICBTYDC-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000001308 synthesis method Methods 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- PFAHOCCFCQWRJZ-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C)C2=CC3=CC=CC=C3C=C2)C)=O)N1 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C)C2=CC3=CC=CC=C3C=C2)C)=O)N1 PFAHOCCFCQWRJZ-UHFFFAOYSA-N 0.000 description 5
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical group [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 5
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- MKARNSWMMBGSHX-UHFFFAOYSA-N 3,5-dimethylaniline Chemical group CC1=CC(C)=CC(N)=C1 MKARNSWMMBGSHX-UHFFFAOYSA-N 0.000 description 4
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- GYUKKKSWBHUUOY-UHFFFAOYSA-N C(C)(=O)C1=C2C=CC=NC2=C(C(=C1)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC)OC Chemical compound C(C)(=O)C1=C2C=CC=NC2=C(C(=C1)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC)OC GYUKKKSWBHUUOY-UHFFFAOYSA-N 0.000 description 4
- UGTSSPSMWDQZIS-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C=2C=C3C=CN(C3=CC2)C)O)C)=O)N1 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C=2C=C3C=CN(C3=CC2)C)O)C)=O)N1 UGTSSPSMWDQZIS-UHFFFAOYSA-N 0.000 description 4
- JFNAZGNEQFDFEN-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C=2N(C=3C(=NC=CC3)N2)C2=CC(=C(C(=C2)C)F)C)C)=O)N1 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C=2N(C=3C(=NC=CC3)N2)C2=CC(=C(C(=C2)C)F)C)C)=O)N1 JFNAZGNEQFDFEN-UHFFFAOYSA-N 0.000 description 4
- YEZKKFPYFGAAAF-XMHGGMMESA-N C1(=CC=CC=C1)/C(=C\C1=CC=CC=C1)/C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC Chemical compound C1(=CC=CC=C1)/C(=C\C1=CC=CC=C1)/C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC YEZKKFPYFGAAAF-XMHGGMMESA-N 0.000 description 4
- XDTBBZWQTVHJCI-UHFFFAOYSA-N C1(CC1)C1=C(C=C(C2=CC=CC=C12)CO)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC Chemical compound C1(CC1)C1=C(C=C(C2=CC=CC=C12)CO)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC XDTBBZWQTVHJCI-UHFFFAOYSA-N 0.000 description 4
- MRALSJJNXUTCSX-UHFFFAOYSA-N C1(CC1)NC(=O)C1=CC2=C(C(N(C=C2C(CCO)C2=NC=CC=C2)C)=O)N1 Chemical compound C1(CC1)NC(=O)C1=CC2=C(C(N(C=C2C(CCO)C2=NC=CC=C2)C)=O)N1 MRALSJJNXUTCSX-UHFFFAOYSA-N 0.000 description 4
- KAPNSVHZGDRLND-UHFFFAOYSA-N CC(C1=CC2=CC=CC=C2C=C1)C3=CN(C(=O)C4=C3C=C(N4)C5=CN(N=C5)C6COC6)C Chemical compound CC(C1=CC2=CC=CC=C2C=C1)C3=CN(C(=O)C4=C3C=C(N4)C5=CN(N=C5)C6COC6)C KAPNSVHZGDRLND-UHFFFAOYSA-N 0.000 description 4
- ZISLSJDNIDKASR-UHFFFAOYSA-N CC(C=CC=C1)=C1N(C(C1=CN(C2COC2)N=C1)=C1)C2=C1C(C(C1=CC=CC=C1)OC)=CN(C)C2=O Chemical compound CC(C=CC=C1)=C1N(C(C1=CN(C2COC2)N=C1)=C1)C2=C1C(C(C1=CC=CC=C1)OC)=CN(C)C2=O ZISLSJDNIDKASR-UHFFFAOYSA-N 0.000 description 4
- CTKBYBTWQKLJRN-UHFFFAOYSA-N CC1=C(C(=CC=C1)C)N1C(=NC2=NC=CC=C21)C=2C1=C(C(N(C2)C)=O)NC(=C1)C(=O)NCC Chemical compound CC1=C(C(=CC=C1)C)N1C(=NC2=NC=CC=C21)C=2C1=C(C(N(C2)C)=O)NC(=C1)C(=O)NCC CTKBYBTWQKLJRN-UHFFFAOYSA-N 0.000 description 4
- FWGNQQHVVDCRAP-UHFFFAOYSA-N CC1CN(C2=C(C1=C=O)NC(=C2)C(=O)NC=2C=NNC2)C(C)C2=CC=CC=C2 Chemical compound CC1CN(C2=C(C1=C=O)NC(=C2)C(=O)NC=2C=NNC2)C(C)C2=CC=CC=C2 FWGNQQHVVDCRAP-UHFFFAOYSA-N 0.000 description 4
- ARKNMFWONHFLOC-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C(=O)NC2CCOCC2)=C=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C(=O)NC2CCOCC2)=C=O ARKNMFWONHFLOC-UHFFFAOYSA-N 0.000 description 4
- JYYNKJGESMFUCC-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C2=CC(=NC=C2)C(F)(F)F)=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C2=CC(=NC=C2)C(F)(F)F)=O JYYNKJGESMFUCC-UHFFFAOYSA-N 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 4
- 102100027086 NUT family member 1 Human genes 0.000 description 4
- 101710137446 NUT family member 1 Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- OEDSFMUSNZDJFD-UHFFFAOYSA-N abbv-744 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C2=C(C=CC(=C2)C(C)(C)O)OC2=C(C=C(C=C2C)F)C)C)=O)N1 OEDSFMUSNZDJFD-UHFFFAOYSA-N 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- WDZVYHXDNNXLFP-UHFFFAOYSA-N pyridin-3-yl carbamate Chemical compound NC(=O)OC1=CC=CN=C1 WDZVYHXDNNXLFP-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- KWJOMJLANYBBDV-UHFFFAOYSA-N 4-bromo-1-methyl-3-nitropyrazole Chemical compound CN1C=C(Br)C([N+]([O-])=O)=N1 KWJOMJLANYBBDV-UHFFFAOYSA-N 0.000 description 3
- PZEBKVLFDUMYSY-UHFFFAOYSA-N 4-bromo-6-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C(=O)N(C)C=C2Br)=C2C=C1 PZEBKVLFDUMYSY-UHFFFAOYSA-N 0.000 description 3
- BXLURABGVGKYCA-UHFFFAOYSA-N 5-(4-methylphenyl)pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1C1NC(=O)CC1 BXLURABGVGKYCA-UHFFFAOYSA-N 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- ISKSDSKZWFMDOM-UHFFFAOYSA-N BrC=1C2=C(C(N(C1)C)=O)NC(=C2)COCC Chemical compound BrC=1C2=C(C(N(C1)C)=O)NC(=C2)COCC ISKSDSKZWFMDOM-UHFFFAOYSA-N 0.000 description 3
- UHILNBLURODGEY-UHFFFAOYSA-N C(=O)CC(=O)O.CC1=NC=CC=C1 Chemical compound C(=O)CC(=O)O.CC1=NC=CC=C1 UHILNBLURODGEY-UHFFFAOYSA-N 0.000 description 3
- SWWYGFBXIYVBAI-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1C=2C(C(N(C1)C)=O)=CNC2 Chemical compound C(C1=CC=CC=C1)C=1C=2C(C(N(C1)C)=O)=CNC2 SWWYGFBXIYVBAI-UHFFFAOYSA-N 0.000 description 3
- WNCAWGRITFAZOP-UHFFFAOYSA-N C1(CC1)C1=NN(C(=C1C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC)C2CC2)C Chemical compound C1(CC1)C1=NN(C(=C1C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NCC)C2CC2)C WNCAWGRITFAZOP-UHFFFAOYSA-N 0.000 description 3
- DQKXHDDGSXIOOG-UHFFFAOYSA-N CC1=CC=C(C=C1)C(C)(C)C2=CN(C(=O)C3=C2C=C(N3)C4=CN(N=C4)C5COC5)C Chemical compound CC1=CC=C(C=C1)C(C)(C)C2=CN(C(=O)C3=C2C=C(N3)C4=CN(N=C4)C5COC5)C DQKXHDDGSXIOOG-UHFFFAOYSA-N 0.000 description 3
- PYTUCTGOQPRHNN-UHFFFAOYSA-N CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=NN3C(C)C4=CC=CC=C4)C(=O)NCC)C Chemical compound CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=NN3C(C)C4=CC=CC=C4)C(=O)NCC)C PYTUCTGOQPRHNN-UHFFFAOYSA-N 0.000 description 3
- RRQONCGDWSBLMQ-UHFFFAOYSA-N CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=NC(=CN3C4=CC=C(C=C4)C)CO)C Chemical compound CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=NC(=CN3C4=CC=C(C=C4)C)CO)C RRQONCGDWSBLMQ-UHFFFAOYSA-N 0.000 description 3
- ATRPLOXBKMDVRY-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C=2C=NN(C2)C2COC2)=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C=2C=NN(C2)C2COC2)=O ATRPLOXBKMDVRY-UHFFFAOYSA-N 0.000 description 3
- FHOKCQZUIXZQHX-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C=2C=NNC2)=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C=2C=NNC2)=O FHOKCQZUIXZQHX-UHFFFAOYSA-N 0.000 description 3
- HOUPVVDUKQVTIF-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=NN(C=C1C1=CC=C(C=C1)C)C)C=C(N2)C(=O)NC=2C=NNC2)=O Chemical compound CN1C(C2=C(C(=C1)C1=NN(C=C1C1=CC=C(C=C1)C)C)C=C(N2)C(=O)NC=2C=NNC2)=O HOUPVVDUKQVTIF-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- FUDUISJGSRZIIQ-UHFFFAOYSA-N N-ethyl-6-methyl-7-oxo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound CCNC(=O)c1cc2c(cn(C)c(=O)c2[nH]1)B1OC(C)(C)C(C)(C)O1 FUDUISJGSRZIIQ-UHFFFAOYSA-N 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 3
- XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- RYGOBSYXIIUFOR-UHFFFAOYSA-N (1-methylpyrazol-4-yl)boronic acid Chemical compound CN1C=C(B(O)O)C=N1 RYGOBSYXIIUFOR-UHFFFAOYSA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- WJUKOGPNGRUXMG-UHFFFAOYSA-N 1,2-dibromo-1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)(Br)C(Cl)(Cl)Br WJUKOGPNGRUXMG-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 2
- ZVDIEXFKTMIHIU-UHFFFAOYSA-N 1-(1-bromoethenyl)-4-chlorobenzene Chemical compound ClC1=CC=C(C(Br)=C)C=C1 ZVDIEXFKTMIHIU-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- WLALDLJCANWJQB-UHFFFAOYSA-N 1-methyl-4-(4-methylphenyl)pyrazol-3-amine Chemical compound C1=CC(C)=CC=C1C1=CN(C)N=C1N WLALDLJCANWJQB-UHFFFAOYSA-N 0.000 description 2
- OKPCAONVUKBJJQ-UHFFFAOYSA-N 1-methylpyrazol-4-amine;hydrochloride Chemical compound Cl.CN1C=C(N)C=N1 OKPCAONVUKBJJQ-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- KFOQLTKNWNGAHL-UHFFFAOYSA-N 3,5-dibromo-1-methylpyrazole Chemical compound CN1N=C(Br)C=C1Br KFOQLTKNWNGAHL-UHFFFAOYSA-N 0.000 description 2
- UQFIWKBFQXGMJD-UHFFFAOYSA-N 3,5-dibromo-1h-pyrazole Chemical compound BrC=1C=C(Br)NN=1 UQFIWKBFQXGMJD-UHFFFAOYSA-N 0.000 description 2
- VWZQUGUWMGUHKU-UHFFFAOYSA-N 3,5-dicyclopropyl-1-methylpyrazole Chemical compound CN1N=C(C2CC2)C=C1C1CC1 VWZQUGUWMGUHKU-UHFFFAOYSA-N 0.000 description 2
- CWNQPIKGKPUCEG-UHFFFAOYSA-N 3-hydroxy-3-(4-methylphenyl)-2H-isoindol-1-one Chemical compound C1=CC(C)=CC=C1C1(O)C2=CC=CC=C2C(=O)N1 CWNQPIKGKPUCEG-UHFFFAOYSA-N 0.000 description 2
- TVOJIBGZFYMWDT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1 TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 2
- LFRWMZSZWBHKDA-UHFFFAOYSA-N 4-bromo-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxylic acid Chemical compound O=C1N(C)C=C(Br)C2=C1NC(C(O)=O)=C2 LFRWMZSZWBHKDA-UHFFFAOYSA-N 0.000 description 2
- IGNFILTZSIUWBS-UHFFFAOYSA-N 4-fluoro-3,5-dimethylaniline Chemical compound CC1=CC(N)=CC(C)=C1F IGNFILTZSIUWBS-UHFFFAOYSA-N 0.000 description 2
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 2
- KFVGEPWMVKZPND-UHFFFAOYSA-N 5-bromo-4-methyl-3-nitropyridin-2-amine Chemical compound CC1=C(Br)C=NC(N)=C1[N+]([O-])=O KFVGEPWMVKZPND-UHFFFAOYSA-N 0.000 description 2
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 2
- WOSYAMNMWPZLGF-UHFFFAOYSA-N 8-fluoro-5-nitroquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=C(F)C2=N1 WOSYAMNMWPZLGF-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 102100037437 Beta-defensin 1 Human genes 0.000 description 2
- ODILVVJQUNNYSU-UHFFFAOYSA-N BrC1=CC(=C2C=CC=NC2=C1C)C(C)(C)O Chemical compound BrC1=CC(=C2C=CC=NC2=C1C)C(C)(C)O ODILVVJQUNNYSU-UHFFFAOYSA-N 0.000 description 2
- FGSSKJXVLJRLJS-UHFFFAOYSA-N BrC1=CC(=C2C=CC=NC2=C1OC)C(C)=O Chemical compound BrC1=CC(=C2C=CC=NC2=C1OC)C(C)=O FGSSKJXVLJRLJS-UHFFFAOYSA-N 0.000 description 2
- KYBYEHIFCNWZJX-UHFFFAOYSA-N BrC=1C(=C(C(N(C1)C)=C=O)[N+](=O)[O-])CC(C(=O)OCC)=C=O Chemical compound BrC=1C(=C(C(N(C1)C)=C=O)[N+](=O)[O-])CC(C(=O)OCC)=C=O KYBYEHIFCNWZJX-UHFFFAOYSA-N 0.000 description 2
- VEJZDEHBJHBQNO-UHFFFAOYSA-N BrC=1C(=NN(C=1CC1CC1)C)CC1CC1 Chemical compound BrC=1C(=NN(C=1CC1CC1)C)CC1CC1 VEJZDEHBJHBQNO-UHFFFAOYSA-N 0.000 description 2
- FABYMBSEYFCWNF-UHFFFAOYSA-N BrC=1C=C(C2=CC=CC=C2C1C1CC1)CO Chemical compound BrC=1C=C(C2=CC=CC=C2C1C1CC1)CO FABYMBSEYFCWNF-UHFFFAOYSA-N 0.000 description 2
- JCNAFJNKARDXJC-UHFFFAOYSA-N BrC=1C=C(C=2C=CC=NC2C1OC)C(=O)OC Chemical compound BrC=1C=C(C=2C=CC=NC2C1OC)C(=O)OC JCNAFJNKARDXJC-UHFFFAOYSA-N 0.000 description 2
- PYGJRWCZIXFPFC-UHFFFAOYSA-N BrC=1N(C=2C(=NC=CC2)N1)C1=CC(=C(C(=C1)C)F)C Chemical compound BrC=1N(C=2C(=NC=CC2)N1)C1=CC(=C(C(=C1)C)F)C PYGJRWCZIXFPFC-UHFFFAOYSA-N 0.000 description 2
- VOYRKJNBTYHCFQ-UHFFFAOYSA-N BrC=1N(C=C(N1)CO)C1=CC=C(C=C1)C Chemical compound BrC=1N(C=C(N1)CO)C1=CC=C(C=C1)C VOYRKJNBTYHCFQ-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 2
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 2
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 2
- NJLDIXYXSQFBGM-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1C=2C(C(N(C1)C)=O)=CN(C2)C(=O)NCC Chemical compound C(C1=CC=CC=C1)C=1C=2C(C(N(C1)C)=O)=CN(C2)C(=O)NCC NJLDIXYXSQFBGM-UHFFFAOYSA-N 0.000 description 2
- PQBGKAVQKOGMKC-UHFFFAOYSA-N CC(C)(C1=CC=C(C)C=C1)C(C(C=C1C2=CN(C3COC3)N=C2)=C2N1C1=C(C)C=CC=C1)=CN(C)C2=O Chemical compound CC(C)(C1=CC=C(C)C=C1)C(C(C=C1C2=CN(C3COC3)N=C2)=C2N1C1=C(C)C=CC=C1)=CN(C)C2=O PQBGKAVQKOGMKC-UHFFFAOYSA-N 0.000 description 2
- SOVMTVUSTDIARU-UHFFFAOYSA-N CC(C=CC=C1)=C1N(C(I)=C1)C2=C1C(CC1=CC=CC=C1)=CN(C)C2=O Chemical compound CC(C=CC=C1)=C1N(C(I)=C1)C2=C1C(CC1=CC=CC=C1)=CN(C)C2=O SOVMTVUSTDIARU-UHFFFAOYSA-N 0.000 description 2
- MVWKAOSUVQGRJT-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C(=O)N(C=C3C(C)C4=CC=CC=C4)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C(=O)N(C=C3C(C)C4=CC=CC=C4)C MVWKAOSUVQGRJT-UHFFFAOYSA-N 0.000 description 2
- VOXWCFFEHPYSRE-UHFFFAOYSA-N CCNC(=O)c1cc2c(Br)cn(C)c(=O)c2[nH]1 Chemical compound CCNC(=O)c1cc2c(Br)cn(C)c(=O)c2[nH]1 VOXWCFFEHPYSRE-UHFFFAOYSA-N 0.000 description 2
- PAPWLCKLQREPKO-UHFFFAOYSA-N CCOC(C1=CC(C(C(C)C2=CC=CC=C2)=CN(C)C2=C=O)=C2N1)=O Chemical compound CCOC(C1=CC(C(C(C)C2=CC=CC=C2)=CN(C)C2=C=O)=C2N1)=O PAPWLCKLQREPKO-UHFFFAOYSA-N 0.000 description 2
- QIUJXPUVWDSCJG-UHFFFAOYSA-N CCOC(C1=CC(C(C(C2=CC=CC=C2)=C)=CN(C)C2=C=O)=C2N1)=O Chemical compound CCOC(C1=CC(C(C(C2=CC=CC=C2)=C)=CN(C)C2=C=O)=C2N1)=O QIUJXPUVWDSCJG-UHFFFAOYSA-N 0.000 description 2
- MIKZACWITHAHHT-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C(=O)O)=C=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C(=O)O)=C=O MIKZACWITHAHHT-UHFFFAOYSA-N 0.000 description 2
- HUALFJULAQNINP-UHFFFAOYSA-N CN1N=C(C(=C1)C1=CC=C(C=C1)C)[N+](=O)[O-] Chemical compound CN1N=C(C(=C1)C1=CC=C(C=C1)C)[N+](=O)[O-] HUALFJULAQNINP-UHFFFAOYSA-N 0.000 description 2
- BYZYHIPPPHMHQB-UHFFFAOYSA-N COC(C=1C2=C(C(N(C1)C)=O)N(C(=C2)C=2C=NN(C2)C)S(=O)(=O)C2=CC=C(C)C=C2)C2=CC=CC=C2 Chemical compound COC(C=1C2=C(C(N(C1)C)=O)N(C(=C2)C=2C=NN(C2)C)S(=O)(=O)C2=CC=C(C)C=C2)C2=CC=CC=C2 BYZYHIPPPHMHQB-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- MRPYOWYPKLPYMR-UHFFFAOYSA-N FC1=C(C=C(C=C1C)N1C(NC2=NC=CC=C21)=S)C Chemical compound FC1=C(C=C(C=C1C)N1C(NC2=NC=CC=C21)=S)C MRPYOWYPKLPYMR-UHFFFAOYSA-N 0.000 description 2
- YYRWPSXSASVKTH-UHFFFAOYSA-N FC1=C(C=C(C=C1C)NC=1C(=NC=CC1)[N+](=O)[O-])C Chemical compound FC1=C(C=C(C=C1C)NC=1C(=NC=CC1)[N+](=O)[O-])C YYRWPSXSASVKTH-UHFFFAOYSA-N 0.000 description 2
- BIKYCRUTXJWHFD-UHFFFAOYSA-N FC1=CC=C(C=C1)C(C)C=1C2=C(C(N(C1)C)=O)N(C=C2)S(=O)(=O)C2=CC=C(C)C=C2 Chemical compound FC1=CC=C(C=C1)C(C)C=1C2=C(C(N(C1)C)=O)N(C=C2)S(=O)(=O)C2=CC=C(C)C=C2 BIKYCRUTXJWHFD-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 2
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- SEQYGSBKGHYSLT-UHFFFAOYSA-N IC1=C2C=CC=NC2=C(C=C1)OC1CC1 Chemical compound IC1=C2C=CC=NC2=C(C=C1)OC1CC1 SEQYGSBKGHYSLT-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- FQSLLUGBAKUGGK-UHFFFAOYSA-N NC1=C2C=CC=NC2=C(C=C1)OC1CC1 Chemical compound NC1=C2C=CC=NC2=C(C=C1)OC1CC1 FQSLLUGBAKUGGK-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- HCNXWQOTOCGKBA-UHFFFAOYSA-N OC(C=1C2=C(C(N(C1)C)=O)N(C=C2)S(=O)(=O)C2=CC=C(C)C=C2)C2=CC=CC=C2 Chemical compound OC(C=1C2=C(C(N(C1)C)=O)N(C=C2)S(=O)(=O)C2=CC=C(C)C=C2)C2=CC=CC=C2 HCNXWQOTOCGKBA-UHFFFAOYSA-N 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 2
- 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000009341 RNA Virus Infections Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- VMBKAERKSNUBRK-UHFFFAOYSA-N [N+](=O)([O-])C1=C2C=CC=NC2=C(C=C1)OC1CC1 Chemical compound [N+](=O)([O-])C1=C2C=CC=NC2=C(C=C1)OC1CC1 VMBKAERKSNUBRK-UHFFFAOYSA-N 0.000 description 2
- MWMRHQNYFJZKDT-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCCC(=O)C1=NC=CC=C1 Chemical compound [Si](C)(C)(C(C)(C)C)OCCC(=O)C1=NC=CC=C1 MWMRHQNYFJZKDT-UHFFFAOYSA-N 0.000 description 2
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000005257 alkyl acyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229950002797 apabetalone Drugs 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- VJRITMATACIYAF-UHFFFAOYSA-N benzenesulfonohydrazide Chemical compound NNS(=O)(=O)C1=CC=CC=C1 VJRITMATACIYAF-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 2
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- NIXOIRLDFIPNLJ-UHFFFAOYSA-M magnesium;benzene;bromide Chemical compound [Mg+2].[Br-].C1=CC=[C-]C=C1 NIXOIRLDFIPNLJ-UHFFFAOYSA-M 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- GDNLLWLWRRVVEZ-UHFFFAOYSA-N methyl 4-(4-methylphenyl)-4-oxobutanoate Chemical compound COC(=O)CCC(=O)C1=CC=C(C)C=C1 GDNLLWLWRRVVEZ-UHFFFAOYSA-N 0.000 description 2
- LDRGRLDNDFQIMI-UHFFFAOYSA-N methyl 6-methyl-1-(4-methylphenyl)sulfonyl-7-oxopyrrolo[2,3-c]pyridine-4-carboxylate Chemical compound CN1C(C2=C(C(=C1)C(=O)OC)C=CN2S(=O)(=O)C1=CC=C(C=C1)C)=O LDRGRLDNDFQIMI-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005029 transcription elongation Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UPNNXUSUOSTIIM-UHFFFAOYSA-N 1,2-dithietane Chemical compound C1CSS1 UPNNXUSUOSTIIM-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- ITXACGPMGJCSKF-UHFFFAOYSA-N 1,3-dithietane Chemical compound C1SCS1 ITXACGPMGJCSKF-UHFFFAOYSA-N 0.000 description 1
- WLRIREROKRGVTD-UHFFFAOYSA-N 1,5-diazacycloundec-5-ene Chemical compound C1CCNCCCN=CCC1 WLRIREROKRGVTD-UHFFFAOYSA-N 0.000 description 1
- RBKXHNWXQBJRSV-UHFFFAOYSA-N 1-(4-methylphenyl)imidazole-4-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C=C(C#N)N=C1 RBKXHNWXQBJRSV-UHFFFAOYSA-N 0.000 description 1
- KIYMAKQVFHPNGB-UHFFFAOYSA-N 1-(oxetan-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C2COC2)N=C1 KIYMAKQVFHPNGB-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- CRRUGYDDEMGVDY-UHFFFAOYSA-N 1-bromoethylbenzene Chemical compound CC(Br)C1=CC=CC=C1 CRRUGYDDEMGVDY-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- SACRVGHAMAASFL-UHFFFAOYSA-N 1-methyl-3-(1-phenylethyl)pyrazole Chemical compound CN1N=C(C=C1)C(C)C1=CC=CC=C1 SACRVGHAMAASFL-UHFFFAOYSA-N 0.000 description 1
- LBGSWBJURUFGLR-UHFFFAOYSA-N 1-methylpyrazol-4-amine Chemical compound CN1C=C(N)C=N1 LBGSWBJURUFGLR-UHFFFAOYSA-N 0.000 description 1
- JQNUBQVFLHNXRC-UHFFFAOYSA-N 1-pyridin-3-ylethenyl trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OC(=C)C=1C=NC=CC=1)(F)F JQNUBQVFLHNXRC-UHFFFAOYSA-N 0.000 description 1
- AXINVSXSGNSVLV-UHFFFAOYSA-N 1h-pyrazol-4-amine Chemical compound NC=1C=NNC=1 AXINVSXSGNSVLV-UHFFFAOYSA-N 0.000 description 1
- KEZNMOUMHOZFRA-UHFFFAOYSA-N 1h-pyrazol-4-ylboronic acid Chemical compound OB(O)C=1C=NNC=1 KEZNMOUMHOZFRA-UHFFFAOYSA-N 0.000 description 1
- KEUDMLLLHGLIGH-UHFFFAOYSA-N 1h-pyrazole;pyrimidine Chemical compound C=1C=NNC=1.C1=CN=CN=C1 KEUDMLLLHGLIGH-UHFFFAOYSA-N 0.000 description 1
- RSFNGIUFEFLHRD-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2NC(C(=O)N)=CC2=C1 RSFNGIUFEFLHRD-UHFFFAOYSA-N 0.000 description 1
- PWWYFIZEQHFRJH-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine-2-carboxylic acid Chemical compound C1=NC=C2NC(C(=O)O)=CC2=C1 PWWYFIZEQHFRJH-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- LXMGXMQQJNULPR-NTISSMGPSA-N 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide hydrate Chemical compound O.Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 LXMGXMQQJNULPR-NTISSMGPSA-N 0.000 description 1
- HTFNVAVTYILUCF-UHFFFAOYSA-N 2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methyl-11-methylsulfonylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(c2n1)S(C)(=O)=O)C(=O)N1CCC(CC1)N1CCN(C)CC1 HTFNVAVTYILUCF-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- BWDPOZOBRAEOTA-UHFFFAOYSA-N 3-(4-methylphenyl)-2,3-dihydroisoindol-1-one Chemical compound C1=CC(C)=CC=C1C1C2=CC=CC=C2C(=O)N1 BWDPOZOBRAEOTA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZHXDQNNFDJRLCZ-UHFFFAOYSA-N 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxazole Chemical compound CC1=NOC=C1B1OC(C)(C)C(C)(C)O1 ZHXDQNNFDJRLCZ-UHFFFAOYSA-N 0.000 description 1
- RMGBWPMWUZSIMH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(1-phenylethenyl)-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C(=C)C1=CC=CC=C1 RMGBWPMWUZSIMH-UHFFFAOYSA-N 0.000 description 1
- ARAINKADEARZLZ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(2-phenylethenyl)-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C=CC1=CC=CC=C1 ARAINKADEARZLZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CUQOVOZIDNPNHO-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC(C(F)(F)F)=C1 CUQOVOZIDNPNHO-UHFFFAOYSA-N 0.000 description 1
- OEEUWZITKKSXAZ-UHFFFAOYSA-N 4-(4-methylphenyl)-4-oxobutanoic acid Chemical compound CC1=CC=C(C(=O)CCC(O)=O)C=C1 OEEUWZITKKSXAZ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- WEQNDTYVEHMMMX-UHFFFAOYSA-N 4-bromo-5-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1NN=CC=1Br WEQNDTYVEHMMMX-UHFFFAOYSA-N 0.000 description 1
- ZRKCSQGCGRFOAU-UHFFFAOYSA-N 4-bromo-6-methyl-1-(4-methylphenyl)sulfonyl-2-(1H-pyrazol-4-yl)pyrrolo[2,3-c]pyridin-7-one Chemical compound BrC=1C2=C(C(N(C1)C)=O)N(C(=C2)C=2C=NNC2)S(=O)(=O)C2=CC=C(C)C=C2 ZRKCSQGCGRFOAU-UHFFFAOYSA-N 0.000 description 1
- SGOWUUBRFPHUIG-UHFFFAOYSA-N 4-bromo-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound O=C1N(C)C=C(Br)C2=C1NC=C2 SGOWUUBRFPHUIG-UHFFFAOYSA-N 0.000 description 1
- GLDCXELPUQJUIQ-UHFFFAOYSA-N 5-bromo-1,4-dimethyl-3-nitropyridin-2-one Chemical compound CC=1C(Br)=CN(C)C(=O)C=1[N+]([O-])=O GLDCXELPUQJUIQ-UHFFFAOYSA-N 0.000 description 1
- VFWZQRFZMKHGOY-UHFFFAOYSA-N 5-bromo-1-methyl-3-nitropyridin-2-one Chemical compound CN1C=C(Br)C=C([N+]([O-])=O)C1=O VFWZQRFZMKHGOY-UHFFFAOYSA-N 0.000 description 1
- FYNCIYHECMWXPK-UHFFFAOYSA-N 5h-furo[3,2-c]pyridin-4-one Chemical compound O=C1NC=CC2=C1C=CO2 FYNCIYHECMWXPK-UHFFFAOYSA-N 0.000 description 1
- DUPNPBCUJHMSFZ-UHFFFAOYSA-N 5h-thieno[3,2-c]pyridin-4-one Chemical compound O=C1NC=CC2=C1C=CS2 DUPNPBCUJHMSFZ-UHFFFAOYSA-N 0.000 description 1
- RAMRPLIWQGMXMT-UHFFFAOYSA-N 6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound N1C(=CC2=C1CNC=C2)C(=O)N RAMRPLIWQGMXMT-UHFFFAOYSA-N 0.000 description 1
- QACAXRSHIFAROF-UHFFFAOYSA-N 6-methyl-1-(4-methylphenyl)sulfonyl-2-(1-methylpyrazol-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-c]pyridin-7-one Chemical compound CN1C(C2=C(C(=C1)B1OC(C(O1)(C)C)(C)C)C=C(N2S(=O)(=O)C1=CC=C(C)C=C1)C=1C=NN(C=1)C)=O QACAXRSHIFAROF-UHFFFAOYSA-N 0.000 description 1
- PUQADTQUYBSRPB-UHFFFAOYSA-N 6-methyl-1-(4-methylphenyl)sulfonyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C(=O)N(C)C=C2B3OC(C)(C)C(C)(C)O3)=C2C=C1 PUQADTQUYBSRPB-UHFFFAOYSA-N 0.000 description 1
- QKICOTLPAQCPPW-UHFFFAOYSA-N 6-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-c]pyridin-7-one Chemical compound CN1C(C2=C(C=C1)C=CN2S(=O)(=O)C1=CC=C(C)C=C1)=O QKICOTLPAQCPPW-UHFFFAOYSA-N 0.000 description 1
- RZVXHNXXRQRLMS-UHFFFAOYSA-N 7-bromo-5-methylfuro[3,2-c]pyridin-4-one Chemical compound Cn1cc(Br)c2occc2c1=O RZVXHNXXRQRLMS-UHFFFAOYSA-N 0.000 description 1
- BKCHHJXWZRPGEF-UHFFFAOYSA-N 7-bromo-5-methylthieno[3,2-c]pyridin-4-one Chemical compound BrC=1C2=C(C(N(C1)C)=O)C=CS2 BKCHHJXWZRPGEF-UHFFFAOYSA-N 0.000 description 1
- YFKFZPQHCJAURO-UHFFFAOYSA-N 7-bromo-5h-furo[3,2-c]pyridin-4-one Chemical compound BrC1=CNC(=O)C2=C1OC=C2 YFKFZPQHCJAURO-UHFFFAOYSA-N 0.000 description 1
- IFGFCNNLXIUQIV-UHFFFAOYSA-N 7-bromo-5h-thieno[3,2-c]pyridin-4-one Chemical compound BrC1=CNC(=O)C2=C1SC=C2 IFGFCNNLXIUQIV-UHFFFAOYSA-N 0.000 description 1
- YPWFNLSXQIGJCK-UHFFFAOYSA-N 7-oxabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1O2 YPWFNLSXQIGJCK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BIRRQJBQDBVZLK-UHFFFAOYSA-N BrC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)NCC Chemical compound BrC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)NCC BIRRQJBQDBVZLK-UHFFFAOYSA-N 0.000 description 1
- DTHOSBOCQILJCC-UHFFFAOYSA-N BrC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)O Chemical compound BrC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)O DTHOSBOCQILJCC-UHFFFAOYSA-N 0.000 description 1
- NTNSKYYCQMEBLN-UHFFFAOYSA-N BrC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)OCC Chemical compound BrC1=C(C=NN1C(C)C1=CC=CC=C1)C(=O)OCC NTNSKYYCQMEBLN-UHFFFAOYSA-N 0.000 description 1
- IEZBPYPZBMBVMF-UHFFFAOYSA-N BrC1=CC=2C(N(C=C(C2S1)C(C)C1=CC=CC=C1)C)=O Chemical compound BrC1=CC=2C(N(C=C(C2S1)C(C)C1=CC=CC=C1)C)=O IEZBPYPZBMBVMF-UHFFFAOYSA-N 0.000 description 1
- YTTFYWVLYSERGE-UHFFFAOYSA-N BrC=1C(=NN(C1)C)C(C)C1=CC=CC=C1 Chemical compound BrC=1C(=NN(C1)C)C(C)C1=CC=CC=C1 YTTFYWVLYSERGE-UHFFFAOYSA-N 0.000 description 1
- PSVYUSDPKQNUCW-UHFFFAOYSA-N BrC=1C2=C(C(NC1)OC)NC=C2 Chemical compound BrC=1C2=C(C(NC1)OC)NC=C2 PSVYUSDPKQNUCW-UHFFFAOYSA-N 0.000 description 1
- KWAGECQDEMUXDJ-UHFFFAOYSA-N BrC=1C=2C(C(N(C1)C)=O)=CNC2 Chemical compound BrC=1C=2C(C(N(C1)C)=O)=CNC2 KWAGECQDEMUXDJ-UHFFFAOYSA-N 0.000 description 1
- LNRTYIAAHBJHEB-UHFFFAOYSA-N BrC=1C=2C(C(N(C1)C)=O)=CNC2C(=O)OCC Chemical compound BrC=1C=2C(C(N(C1)C)=O)=CNC2C(=O)OCC LNRTYIAAHBJHEB-UHFFFAOYSA-N 0.000 description 1
- HTRANUGTQJLUNR-UHFFFAOYSA-N BrC=1C=C(C2=CC=CC=C2C1OC1CC1)C(=O)OC Chemical compound BrC=1C=C(C2=CC=CC=C2C1OC1CC1)C(=O)OC HTRANUGTQJLUNR-UHFFFAOYSA-N 0.000 description 1
- GHBSYDHYAZMRSY-UHFFFAOYSA-N BrC=1N(C=C(N1)C#N)C1=CC=C(C=C1)C Chemical compound BrC=1N(C=C(N1)C#N)C1=CC=C(C=C1)C GHBSYDHYAZMRSY-UHFFFAOYSA-N 0.000 description 1
- IQLPFUUMSIQKCB-UHFFFAOYSA-N BrC=1N(C=C(N1)C(=O)OC)C1=CC=C(C=C1)C Chemical compound BrC=1N(C=C(N1)C(=O)OC)C1=CC=C(C=C1)C IQLPFUUMSIQKCB-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- GJJCDKKIXRZFSM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)C1(N=NC=C1)N Chemical compound C(C)(C)(C)OC(=O)C1(N=NC=C1)N GJJCDKKIXRZFSM-UHFFFAOYSA-N 0.000 description 1
- RTHVUEIRFVBMRU-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C(=C)C2=CC3=CC=CC=C3C=C2)C)=O)N1 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C(=C)C2=CC3=CC=CC=C3C=C2)C)=O)N1 RTHVUEIRFVBMRU-UHFFFAOYSA-N 0.000 description 1
- XJYHVFNWFLIHKL-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C(=C)C=2C=NC=CC2)C)=O)N1 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C(=C)C=2C=NC=CC2)C)=O)N1 XJYHVFNWFLIHKL-UHFFFAOYSA-N 0.000 description 1
- OEISCRUFFQRRLB-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C)C2=CC=CC=C2)C)=O)N1 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C)C2=CC=CC=C2)C)=O)N1 OEISCRUFFQRRLB-UHFFFAOYSA-N 0.000 description 1
- LDEXXWGFHZQHSJ-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C2=CC=CC=C2)O)C)=O)N1COCC[Si](C)(C)C Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C(C2=CC=CC=C2)O)C)=O)N1COCC[Si](C)(C)C LDEXXWGFHZQHSJ-UHFFFAOYSA-N 0.000 description 1
- WXOBCKIOFHQFHJ-UHFFFAOYSA-N C(C)NC(=O)C1=CC2=C(C(N(C=C2C2=CC(=C3C=CC=NC3=C2C)C(C)(C)O)C)=O)N1 Chemical compound C(C)NC(=O)C1=CC2=C(C(N(C=C2C2=CC(=C3C=CC=NC3=C2C)C(C)(C)O)C)=O)N1 WXOBCKIOFHQFHJ-UHFFFAOYSA-N 0.000 description 1
- VXEYFCKNOLELHI-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NNCC Chemical compound C(C1=CC=CC=C1)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)NNCC VXEYFCKNOLELHI-UHFFFAOYSA-N 0.000 description 1
- MUPPHQXBKHCBTE-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1C=2C(C(N(C1)C)=O)=CN(C2)C(=O)OC2=CC=C(C=C2)[N+](=O)[O-] Chemical compound C(C1=CC=CC=C1)C=1C=2C(C(N(C1)C)=O)=CN(C2)C(=O)OC2=CC=C(C=C2)[N+](=O)[O-] MUPPHQXBKHCBTE-UHFFFAOYSA-N 0.000 description 1
- LRIYBEBCHJMSHM-UHFFFAOYSA-N C1(CC1)OC1=CC=C(C2=CC=CC=C12)C(=O)OC Chemical compound C1(CC1)OC1=CC=C(C2=CC=CC=C12)C(=O)OC LRIYBEBCHJMSHM-UHFFFAOYSA-N 0.000 description 1
- QVYUZCMYSTVRMN-UHFFFAOYSA-N C1(CC1)OC1=CC=C(C2=CC=CC=C12)I Chemical compound C1(CC1)OC1=CC=C(C2=CC=CC=C12)I QVYUZCMYSTVRMN-UHFFFAOYSA-N 0.000 description 1
- KEMMTQCNIPZDRS-UHFFFAOYSA-N C1=CC=C(C=C1)N2C(=CC3=C2C(=O)NC=C3)C(=O)N Chemical compound C1=CC=C(C=C1)N2C(=CC3=C2C(=O)NC=C3)C(=O)N KEMMTQCNIPZDRS-UHFFFAOYSA-N 0.000 description 1
- NCUUKQZLQLGVCY-UHFFFAOYSA-N C1CCOC1.C1=CN=C2C1=CC=NC2=O Chemical compound C1CCOC1.C1=CN=C2C1=CC=NC2=O NCUUKQZLQLGVCY-UHFFFAOYSA-N 0.000 description 1
- UUSRONNQOOUXPT-UHFFFAOYSA-N CC(C(C=C1)=CC=C1F)C1=CN(C)CC2=C1C=CN2S(C1=CC=C(C)C=C1)(=O)=O Chemical compound CC(C(C=C1)=CC=C1F)C1=CN(C)CC2=C1C=CN2S(C1=CC=C(C)C=C1)(=O)=O UUSRONNQOOUXPT-UHFFFAOYSA-N 0.000 description 1
- XUUDHUFAULNLLP-UHFFFAOYSA-N CC(C1=CC2=CC=CC=C2C=C1)C(C(C=C1C2=CN(C3COC3)N=C2)=C2N1C1=C(C)C=CC=C1)=CN(C)C2=O Chemical compound CC(C1=CC2=CC=CC=C2C=C1)C(C(C=C1C2=CN(C3COC3)N=C2)=C2N1C1=C(C)C=CC=C1)=CN(C)C2=O XUUDHUFAULNLLP-UHFFFAOYSA-N 0.000 description 1
- HQAXHZZJFVEOAY-UHFFFAOYSA-N CC(C1=CC=C(C=C1)Cl)C2=CN(C(=O)C3=C2C=C(N3)C(=O)O)C Chemical compound CC(C1=CC=C(C=C1)Cl)C2=CN(C(=O)C3=C2C=C(N3)C(=O)O)C HQAXHZZJFVEOAY-UHFFFAOYSA-N 0.000 description 1
- GQLBHCYGDBIAOU-UHFFFAOYSA-N CC(C1=CC=CC=C1)C1=CN(C)CC2=C1C=C(C1=CNN=C1)N2 Chemical compound CC(C1=CC=CC=C1)C1=CN(C)CC2=C1C=C(C1=CNN=C1)N2 GQLBHCYGDBIAOU-UHFFFAOYSA-N 0.000 description 1
- DNTXNGJSDANNHW-UHFFFAOYSA-N CC(C1=CC=CC=C1)C2=CC3=C(O2)C=CNC3=O Chemical compound CC(C1=CC=CC=C1)C2=CC3=C(O2)C=CNC3=O DNTXNGJSDANNHW-UHFFFAOYSA-N 0.000 description 1
- FOILGRIDWPIEDB-UHFFFAOYSA-N CC(C1=CC=CC=C1)C2=CN(C(=O)C3=C2OC(=C3)Br)C Chemical compound CC(C1=CC=CC=C1)C2=CN(C(=O)C3=C2OC(=C3)Br)C FOILGRIDWPIEDB-UHFFFAOYSA-N 0.000 description 1
- YKDNOOPNXXZSDN-UHFFFAOYSA-N CC(C1=CC=CC=C1)C2=CN(C(=O)C3=C2OC=C3)C Chemical compound CC(C1=CC=CC=C1)C2=CN(C(=O)C3=C2OC=C3)C YKDNOOPNXXZSDN-UHFFFAOYSA-N 0.000 description 1
- AVWZVVYQAFAFBF-UHFFFAOYSA-N CC(C1=CC=CC=C1)N(CC(C)C1=C=O)C2=C1NC(C(NC1=CN(C(OC(C)(C)C)=O)N=C1)=O)=C2 Chemical compound CC(C1=CC=CC=C1)N(CC(C)C1=C=O)C2=C1NC(C(NC1=CN(C(OC(C)(C)C)=O)N=C1)=O)=C2 AVWZVVYQAFAFBF-UHFFFAOYSA-N 0.000 description 1
- DNXUJCAHJYPILD-UHFFFAOYSA-N CC(C=CC=C1)=C1N(C(C1=CN(C2COC2)N=C1)=C1)C2=C1C(C(C1=CC3=CC=CC=C3C=C1)=C)=CN(C)C2=O Chemical compound CC(C=CC=C1)=C1N(C(C1=CN(C2COC2)N=C1)=C1)C2=C1C(C(C1=CC3=CC=CC=C3C=C1)=C)=CN(C)C2=O DNXUJCAHJYPILD-UHFFFAOYSA-N 0.000 description 1
- DUCHBFLYSROERV-UHFFFAOYSA-N CC1(C)OB(C(C=CN(C)C2)=C2[N+]([O-])=O)OC1(C)C Chemical compound CC1(C)OB(C(C=CN(C)C2)=C2[N+]([O-])=O)OC1(C)C DUCHBFLYSROERV-UHFFFAOYSA-N 0.000 description 1
- PSPINKOWBASDNO-UHFFFAOYSA-N CC1=CC=C(C=C1)C(C)(C)C2=CN(C(=O)C3=C2C=CN3)C Chemical compound CC1=CC=C(C=C1)C(C)(C)C2=CN(C(=O)C3=C2C=CN3)C PSPINKOWBASDNO-UHFFFAOYSA-N 0.000 description 1
- NMSHUOSOWRLSRJ-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)N2C(=CC3=C2C(=O)N(C=C3C(C)C4=CC=CC=C4)C)C5=CN(N=C5)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N2C(=CC3=C2C(=O)N(C=C3C(C)C4=CC=CC=C4)C)C5=CN(N=C5)C NMSHUOSOWRLSRJ-UHFFFAOYSA-N 0.000 description 1
- JSEHEEOYNUATSV-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)N2C(=CC3=C2C(=O)N(C=C3C(C)C4=CC=CC=C4)C)C5=CNN=C5 Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N2C(=CC3=C2C(=O)N(C=C3C(C)C4=CC=CC=C4)C)C5=CNN=C5 JSEHEEOYNUATSV-UHFFFAOYSA-N 0.000 description 1
- ZAICSKLWXZLJIE-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C(=O)N(C=C3C(=C)C4=CC=C(C=C4)F)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C(=O)N(C=C3C(=C)C4=CC=C(C=C4)F)C ZAICSKLWXZLJIE-UHFFFAOYSA-N 0.000 description 1
- YUSDRJLXGDKTRD-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C(=O)N(C=C3C(=C)C4=CC=CC=C4)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C(=O)N(C=C3C(=C)C4=CC=CC=C4)C YUSDRJLXGDKTRD-UHFFFAOYSA-N 0.000 description 1
- NPRLBSRCBVEVMA-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2CN(C=C3C(=C)C4=CC=C(C=C4)F)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2CN(C=C3C(=C)C4=CC=C(C=C4)F)C NPRLBSRCBVEVMA-UHFFFAOYSA-N 0.000 description 1
- CODUFBYSFIJISZ-UHFFFAOYSA-N CC=1C=C(C=C(C1)C)N1C(=NC2=NC=CC=C21)C=2C1=C(C(N(C2)C)=O)N(C(=C1)C=1C=NN(C1)C)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound CC=1C=C(C=C(C1)C)N1C(=NC2=NC=CC=C21)C=2C1=C(C(N(C2)C)=O)N(C(=C1)C=1C=NN(C1)C)S(=O)(=O)C1=CC=C(C)C=C1 CODUFBYSFIJISZ-UHFFFAOYSA-N 0.000 description 1
- IXRCVZAXINMAJB-UHFFFAOYSA-N CC=1C=C(C=C(C1)C)N1C(=NC2=NC=CC=C21)C=2C1=C(C(N(C2)C)=O)NC(=C1)C=1C=NN(C1)C Chemical compound CC=1C=C(C=C(C1)C)N1C(=NC2=NC=CC=C21)C=2C1=C(C(N(C2)C)=O)NC(=C1)C=1C=NN(C1)C IXRCVZAXINMAJB-UHFFFAOYSA-N 0.000 description 1
- CXSJETMGDMVXDN-UHFFFAOYSA-N CCOC(=O)C1=CC2=C(N1S(=O)(=O)C3=CC=C(C=C3)C)C(=O)N(C=C2C=O)C Chemical compound CCOC(=O)C1=CC2=C(N1S(=O)(=O)C3=CC=C(C=C3)C)C(=O)N(C=C2C=O)C CXSJETMGDMVXDN-UHFFFAOYSA-N 0.000 description 1
- WCZDITFSAVEFEO-UHFFFAOYSA-N CCOC(C1=CC(C(C(C)C(C=C2)=CC=C2Cl)=CN(C)C2=O)=C2N1C1=C(C)C=CC=C1)=O Chemical compound CCOC(C1=CC(C(C(C)C(C=C2)=CC=C2Cl)=CN(C)C2=O)=C2N1C1=C(C)C=CC=C1)=O WCZDITFSAVEFEO-UHFFFAOYSA-N 0.000 description 1
- XMFTWEVNEVUNPP-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(=C)C1=CC=CC=C1)SC=C2)=O Chemical compound CN1C(C2=C(C(=C1)C(=C)C1=CC=CC=C1)SC=C2)=O XMFTWEVNEVUNPP-UHFFFAOYSA-N 0.000 description 1
- YLGQJUVCFYOXNJ-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C(=O)NC=2C=NN(C2)C)=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2)C(=O)NC=2C=NN(C2)C)=O YLGQJUVCFYOXNJ-UHFFFAOYSA-N 0.000 description 1
- MBGYXUSRMHFFPB-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2S(=O)(=O)C2=CC=C(C)C=C2)C2=CC(=NC=C2)C(F)(F)F)=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)C=C(N2S(=O)(=O)C2=CC=C(C)C=C2)C2=CC(=NC=C2)C(F)(F)F)=O MBGYXUSRMHFFPB-UHFFFAOYSA-N 0.000 description 1
- ACGMYJBYILLZGX-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)SC=C2)=O Chemical compound CN1C(C2=C(C(=C1)C(C)C1=CC=CC=C1)SC=C2)=O ACGMYJBYILLZGX-UHFFFAOYSA-N 0.000 description 1
- XTLBQRIXWLLHHR-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=NN(C=C1C1=CC=C(C=C1)C)C)C=C(N2)C(=O)O)=O Chemical compound CN1C(C2=C(C(=C1)C1=NN(C=C1C1=CC=C(C=C1)C)C)C=C(N2)C(=O)O)=O XTLBQRIXWLLHHR-UHFFFAOYSA-N 0.000 description 1
- XCOIKWGYCHWZOT-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C=O)C=CN2S(=O)(=O)C2=CC=C(C)C=C2)=O Chemical compound CN1C(C2=C(C(=C1)C=O)C=CN2S(=O)(=O)C2=CC=C(C)C=C2)=O XCOIKWGYCHWZOT-UHFFFAOYSA-N 0.000 description 1
- LKTXXMHKDVGUMR-UHFFFAOYSA-N CN1C=C(C2=C(C1=O)C=CO2)C(=C)C3=CC=CC=C3 Chemical compound CN1C=C(C2=C(C1=O)C=CO2)C(=C)C3=CC=CC=C3 LKTXXMHKDVGUMR-UHFFFAOYSA-N 0.000 description 1
- ZGRZTLXYDQAHLO-UHFFFAOYSA-N CN1C=C(C2=C(C1=O)NC(=C2)C3=CN(N=C3)C4COC4)C(=O)C5=CC=CC=C5 Chemical compound CN1C=C(C2=C(C1=O)NC(=C2)C3=CN(N=C3)C4COC4)C(=O)C5=CC=CC=C5 ZGRZTLXYDQAHLO-UHFFFAOYSA-N 0.000 description 1
- CVXJUDDQXGYYLU-UHFFFAOYSA-N CN1N=C(C=C1)C(=C)C1=CC=CC=C1 Chemical compound CN1N=C(C=C1)C(=C)C1=CC=CC=C1 CVXJUDDQXGYYLU-UHFFFAOYSA-N 0.000 description 1
- AVQYHGRPIWXONB-UHFFFAOYSA-N COC(C=1C=2C(C(N(C1)C)=O)=CNC2)C2=CC=CC=C2 Chemical compound COC(C=1C=2C(C(N(C1)C)=O)=CNC2)C2=CC=CC=C2 AVQYHGRPIWXONB-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000004449 DNA Virus Infections Diseases 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000035762 Disorder of lipid metabolism Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- HOUWOHRBIWRLDB-UHFFFAOYSA-N FC1=C(C=C(C=C1C)NC=1C(=NC=CC1)N)C Chemical compound FC1=C(C=C(C=C1C)NC=1C(=NC=CC1)N)C HOUWOHRBIWRLDB-UHFFFAOYSA-N 0.000 description 1
- ALMDTMNGQBOMEO-UHFFFAOYSA-N FC1=CC=C(C=C1)C(C)C=1C2=C(C(N(C1)C)=O)N(C(=C2)C=2C=NNC2)S(=O)(=O)C2=CC=C(C)C=C2 Chemical compound FC1=CC=C(C=C1)C(C)C=1C2=C(C(N(C1)C)=O)N(C(=C2)C=2C=NNC2)S(=O)(=O)C2=CC=C(C)C=C2 ALMDTMNGQBOMEO-UHFFFAOYSA-N 0.000 description 1
- SPIMKCBMJLQXSV-UHFFFAOYSA-N FC1=CC=C(C=C1)C(C)C=1C2=C(C(N(C1)C)=O)N(C(=C2)I)S(=O)(=O)C2=CC=C(C)C=C2 Chemical compound FC1=CC=C(C=C1)C(C)C=1C2=C(C(N(C1)C)=O)N(C(=C2)I)S(=O)(=O)C2=CC=C(C)C=C2 SPIMKCBMJLQXSV-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- GZDVNHDMZMRVFM-UHFFFAOYSA-N IC1=NN(C=C1C1=CC=C(C=C1)C)C Chemical compound IC1=NN(C=C1C1=CC=C(C=C1)C)C GZDVNHDMZMRVFM-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LFMZUMUOUJYEJA-UHFFFAOYSA-N OC(C=1C=2C(C(N(C1)C)=O)=CN(C2)COCC[Si](C)(C)C)C2=CC=CC=C2 Chemical compound OC(C=1C=2C(C(N(C1)C)=O)=CN(C2)COCC[Si](C)(C)C)C2=CC=CC=C2 LFMZUMUOUJYEJA-UHFFFAOYSA-N 0.000 description 1
- PYQNHVPWKYSOOS-UHFFFAOYSA-N OCC=1C2=C(C(N(C1)C)=O)N(C=C2)S(=O)(=O)C2=CC=C(C)C=C2 Chemical compound OCC=1C2=C(C(N(C1)C)=O)N(C=C2)S(=O)(=O)C2=CC=C(C)C=C2 PYQNHVPWKYSOOS-UHFFFAOYSA-N 0.000 description 1
- SQSUERUXSNGOFO-UHFFFAOYSA-N OCCC(C1=NC=CC=C1)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)O Chemical compound OCCC(C1=NC=CC=C1)C=1C2=C(C(N(C1)C)=O)NC(=C2)C(=O)O SQSUERUXSNGOFO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- LWQRBUVHPGJMCY-UHFFFAOYSA-N P(=O)(=O)[C-]1C=CC=C1.[CH-]1C=CC=C1.[Fe+2] Chemical compound P(=O)(=O)[C-]1C=CC=C1.[CH-]1C=CC=C1.[Fe+2] LWQRBUVHPGJMCY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 101710132457 Protein A1 Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 206010063544 Renal embolism Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- KJXXUWGVBVJAMQ-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCC=C(C1=NC=CC=C1)OS(=O)(=O)C(F)(F)F Chemical compound [Si](C)(C)(C(C)(C)C)OCC=C(C1=NC=CC=C1)OS(=O)(=O)C(F)(F)F KJXXUWGVBVJAMQ-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical group C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- HTJWUNNIRKDDIV-UHFFFAOYSA-N bis(1-adamantyl)-butylphosphane Chemical compound C1C(C2)CC(C3)CC2CC13P(CCCC)C1(C2)CC(C3)CC2CC3C1 HTJWUNNIRKDDIV-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- QABCGOSYZHCPGN-UHFFFAOYSA-N chloro(dimethyl)silicon Chemical compound C[Si](C)Cl QABCGOSYZHCPGN-UHFFFAOYSA-N 0.000 description 1
- YGHUUVGIRWMJGE-UHFFFAOYSA-N chlorodimethylsilane Chemical compound C[SiH](C)Cl YGHUUVGIRWMJGE-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- XBIMXRVVZSNNGI-UHFFFAOYSA-N ethanamine;oxolane Chemical compound CCN.C1CCOC1 XBIMXRVVZSNNGI-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- STTGPAQEZKUXGD-UHFFFAOYSA-N ethyl 1-(1-phenylethyl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C(C)C1=CC=CC=C1 STTGPAQEZKUXGD-UHFFFAOYSA-N 0.000 description 1
- GWQJRVCTFVYPBK-UHFFFAOYSA-N ethyl 1h-pyrrolo[2,3-c]pyridine-2-carboxylate Chemical compound C1=NC=C2NC(C(=O)OCC)=CC2=C1 GWQJRVCTFVYPBK-UHFFFAOYSA-N 0.000 description 1
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- HBEFVZMJESQFJR-UHFFFAOYSA-N isocyanatosulfanylbenzene Chemical compound O=C=NSC1=CC=CC=C1 HBEFVZMJESQFJR-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- RDONXGFGWSSFMY-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F RDONXGFGWSSFMY-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- ISFGCZIEXMTLLA-UHFFFAOYSA-N oxido-oxo-(1,3,5,7-tetramethyl-8-phenyl-2,4,6-trioxatricyclo[3.3.1.13,7]decan-8-yl)phosphanium Chemical compound CC12OC3(OC(C(C(O1)(C3)C)(P(=O)=O)C1=CC=CC=C1)(C2)C)C ISFGCZIEXMTLLA-UHFFFAOYSA-N 0.000 description 1
- GSUBXIVOZXWGKF-UHFFFAOYSA-N oxolane-3-carbaldehyde Chemical compound O=CC1CCOC1 GSUBXIVOZXWGKF-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 241001147420 ssDNA viruses Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JJXOIFHXNBFRNV-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C JJXOIFHXNBFRNV-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- FAGLEPBREOXSAC-UHFFFAOYSA-N tert-butyl isocyanide Chemical compound CC(C)(C)[N+]#[C-] FAGLEPBREOXSAC-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- MKBQBFPNTLPOIV-UHFFFAOYSA-N tributylstannylmethanol Chemical compound CCCC[Sn](CO)(CCCC)CCCC MKBQBFPNTLPOIV-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention belongs to the field of medicinal chemistry. Specifically, the present invention relates to a new class of compounds, their deuterated compounds, stereoisomers, racemates, geometric isomers, tautomers, prodrugs, hydrates, solvates or their pharmaceutically Acceptable salts, as well as pharmaceutical compositions containing them, are BRD4-targeting inhibitors with novel structures.
- Bromodomain is a protein domain that can recognize acetylated lysine residues. This recognition is a prerequisite for the binding of some regulatory proteins and histones and the remodeling of chromatin structure.
- Bromodomain-containing proteins (BCPs) are divided into 8 families according to the similarity of structure and sequence. The BET family is currently the most researched family, which includes four members: BRD4, BRD3, BRD2 and BRDT .
- the BET bromodomain protein contains several modular structures: two N-terminal series BRDs (BD1 and BD2) are involved in acetylation recognition; an additional protein-protein interaction region (ET); BRDT and long mutants of BRD4 (BRD4L) all contain a C-terminal region (CTM) that interacts with the forward transcription elongation factor (P-TEFb); a conserved region and a serine-glutamate-aspartate-rich region (SEED).
- CTM C-terminal region
- P-TEFb forward transcription elongation factor
- SEED serine-glutamate-aspartate-rich region
- BRD3 and BRD4 are erroneously fused with Nuclear Protein in Testis (NUT) in the testis, leading to the occurrence of adenocarcinoma in the NUT.
- NUT Nuclear Protein in Testis
- BRD4 protein can combine with RNA polymerase II (Pol II) and positive transcription elongation factor (P-TEFb) to participate in the transcription process of oncogenes such as MYC, BCL2 and BCL6.
- Poly II RNA polymerase II
- P-TEFb positive transcription elongation factor
- BRD4 protein occupies the gene position of the super enhancer, allowing cancer cells to maintain a relatively immature stem-like state, which drives cancer to a certain extent.
- BRD4 tumor cell apoptosis or proliferation can be induced, thereby achieving anti-tumor effects. Therefore, BRD4, as a promising anti-tumor target, has received extensive attention and development in recent years.
- the compound Mivebresib (ABBV-075) is a pyridone BRD4 targeting inhibitor developed by Abbvie, which shows good DMPK properties.
- the compound has shown good biological activity in various tumor models, and is currently in the phase I clinical research phase for the treatment of solid tumors and hematological cancers.
- the compound Apabetalone (RVX-208) is derived from a plant polyphenol-resveratrol derivative.
- the compound was originally developed by the Resverlogix, BRD4 BD2 shown to be stronger inhibitory activity (K d of BRD4-BD2 is 135Nm, for K d BRD4-BD1 was 1142nM).
- Apabetalone (RVX-208) can effectively reduce the blood lipids of hyperlipidemia diabetic patients.
- the research for the treatment of prediabetes is in the second clinical phase, and the research for the treatment of atherosclerosis and acute coronary syndrome (ACS) is in the third clinical phase.
- ACS acute coronary syndrome
- CPI-0610 is a compound developed by the company Constellation isoxazol structure BRD4 inhibitor for BRD4-BD1 IC 50 of 35nM, BRD4-BD2 IC 50 of 6nM, a weak selectivity BD2.
- BRD4-BD1 IC 50 of 35nM BRD4-BD1 IC 50 of 35nM
- BRD4-BD2 IC 50 of 6nM a weak selectivity BD2.
- the currently reported Abbv744 is the only BRD4-BD2 selective inhibitor for tumors with a selectivity (BD2/BD1)>100 times.
- Preclinical data indicate that the BD2 selective inhibitor Abbv744 has better safety. It is used for hematoma and solid tumor and is in the first clinical stage.
- BRD4 inhibitors As a single drug or combination drug in the field of tumors and other diseases, they have been found to be more efficient and effective. It is still essential that safe BRD4 inhibitors meet the needs of patients.
- the purpose of the present invention is to provide a compound with BRD4 inhibitory activity, its preparation method and use.
- the first aspect of the present invention provides a compound of formula (I), its deuterated compound, stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, and solvate Or its pharmaceutically acceptable salt:
- Ring A is a five-membered heteroaromatic ring, X 1 , X 2 and X 3 are each independently selected from C, N, O and S and are not C at the same time; preferably, one of X 1 , X 2 and X 3 is N , The other two are C;
- R 3 , R 2 , and R 4 are respectively substituents on X 1 , X 2 and X 3 or not present;
- R 2 is selected from H, -COO-R 6 , -CO-NH-R 6 , -NH-CO-R 6 , -SO 2 -NHR 6 , unsubstituted or substituted 5-8 membered heteroaryl, unsubstituted Or substituted C1-C6 alkyl; wherein, the substitution refers to being substituted by one or more substituents selected from the following: unsubstituted or substituted by one or more substituents selected from C group C1- C6 alkyl, halogen, hydroxy, C5-C8 aryl, 5-8 membered heteroaryl, 3-12 membered heterocycloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkane Oxy, C1-C6 ester, C1-C6 alkoxycarbonyl, nitro, cyano, C1-C6 alkyl amide, unsubstituted or substituted
- R 3 is C1-C6 alkyl, halogen, unsubstituted or amino substituted with an amino protecting agent (such as boc, Cbz, Fmoc, etc.), C1-C6 alkyl amide, nitro, cyano, carboxy or hydrogen, preferably Is hydrogen;
- an amino protecting agent such as boc, Cbz, Fmoc, etc.
- the compound is:
- R 1 , R 2 , R 3 , and R 4 have the same definitions as before.
- the compound is:
- R 1 , R 3 , R 6 are as defined above; Ra, Rb, Rc, and Rd are each independently selected from hydrogen, halogen, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted An amino group substituted by one or more substituents selected from the group D, a C1-C6 alkyl amide group, a nitro group, a 3-12 membered heterocycloalkyl group; the group D substituent includes: a C1-C6 alkyl group, Halogenated C1-C6 alkyl, C1-C6 alkyl amide, C3-C6 cycloalkyl.
- one of R 1 and R 4 is hydrogen or not present, and the other is selected from unsubstituted or substituted C1-C4 alkyl, unsubstituted or substituted C2-C4 alkenyl, unsubstituted or substituted C3-C6 cycloalkyl, unsubstituted or substituted N-containing 5-membered heterocycloalkyl, unsubstituted or substituted amino, unsubstituted or substituted N-containing 5-10 membered heteroaryl, unsubstituted or substituted Naphthyl, unsubstituted or substituted C1-C6 alkylaminoacyl;
- the group A substituents include: amino, nitro, cyano, hydroxy, halogen, phenyl, unsubstituted or halogenated C3-C8 cycloalkyl, unsubstituted or halogenated C3-C8 cycloalkoxy;
- the group B substituents include: C1-C4 alkyl, nitro, cyano, fluorine, chlorine, bromine, trifluoromethoxy, hydroxyl, hydroxymethyl, amino, C1-C4 alkoxy, C3-C6 Cycloalkoxy, 4-8 membered heterocycloalkyl that is unsubstituted or substituted by C1-C6 alkyl, C1-C6 ester group, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 alkane Group amino acyl group, C1-C6 alkyl amide group, -SO-(C1-C6 alkyl), -SO 2 -(C1-C6 alkyl).
- N-containing 5-membered heterocycloalkyl group is N-containing 5-membered heterocycloalkyl group
- N-containing 5-10 membered heteroaryl group is selected from:
- one of R 1 and R 4 is hydrogen, halogen or absent, and the other is selected from:
- Y 1 , Y 2 and Y 3 are selected from C and N respectively and are not nitrogen at the same time;
- R 7 is selected from hydrogen, unsubstituted or halogenated C1-C5 alkyl, unsubstituted or halogenated C3-C8 cycloalkyl, hydroxy, hydroxy substituted C1-C4 alkyl, methoxy, halogen, phenyl , Benzyl, phenoxy, trifluoromethyl substituted phenoxy, trifluoromethoxy, trifluoromethoxy substituted phenoxy, 5-8 membered heteroaryl, 3-8 membered heterocycle alkyl;
- R 8 is a substituent on the phenyl or six-membered heteroaryl group, m is the number of substituent R 8 and m is selected from an integer of 0 to 4 (m is preferably 0, 1, 2); when m ⁇ 2 When R 8 is the same or different; the substituents represented by R 8 are each independently selected from: hydrogen, C1-C6 alkyl, nitro, cyano, halogen, trifluoromethoxy, hydroxy, hydroxymethyl, amino , C1-C6 alkoxy, C3-C6 cycloalkoxy, unsubstituted or 3-8 membered heterocycloalkyl substituted with C1-C6 alkyl;
- R 9 is the substituent on the naphthyl group, n is the number of substituent R 9 , n is selected from an integer of 0-4 (n is preferably 0, 1, 2); when n ⁇ 2, R 9 is the same or Different; the substituents represented by R 9 are each independently selected from: C1-C6 alkyl, nitro, cyano, halogen, trifluoromethoxy, hydroxy, hydroxymethyl, amino, C1-C6 alkoxy, C3-C6 cycloalkoxy, unsubstituted or 4-8 membered heterocycloalkyl substituted with C1-C6 alkyl;
- R 10 is the substituent on the phenyl group, j is the number of substituent R 10 , j is selected from an integer of 0-4 (j is preferably 0, 1, 2); when j ⁇ 2, R 10 is the same or Different; the substituents represented by R 10 are each independently selected from: C1-C6 alkyl, nitro, cyano, halogen, trifluoromethoxy, hydroxy, hydroxymethyl, amino, C1-C6 alkoxy, C3-C6 cycloalkoxy;
- R 11 is selected from hydrogen or C1-C6 alkyl
- R 12 and R 13 are each independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, C1-C6 alkylcarbonyl, C1-C6 alkoxy, amino, and hydroxyl , C1-C6 alkyl substituted with hydroxy;
- R 14 is selected from C1-C6 alkyl group, C1-C6 ester group, C1-C6 alkoxycarbonyl group, C1-C6 alkylamino acyl group, C1-C6 alkyl amide group;
- R 15 , R 16 , and R 17 are each independently selected from hydrogen, C1-C6 alkyl, phenyl substituted C1-C6 alkyl, C3-C6 cycloalkyl, cyclohexyl substituted C1-C6 alkyl, phenyl , C1-C6 alkyl substituted phenyl, hydroxy, hydroxymethyl, hydroxyethyl, trifluoromethoxy, C1-C6 alkoxy, C1-C6 alkylcarbonyl, C1-C6 ester group, C1-C6 Alkoxycarbonyl, C1-C6 alkylaminoacyl, C1-C6 alkylamido, phenoxy;
- R 18 is selected from hydrogen, C1-C6 alkyl, and hydroxyl
- R 19 is selected from unsubstituted or selected from halogen, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C1-C6 alkoxy, hydroxyl, -SO- (C1-C6 alkyl), -SO 2 - one or more (C1-C6 alkyl) and substituted phenyl.
- R 2 is selected from H, -COO-R6, -CO-NH-R 6 , -NH-CO-R 6 , -SO 2 -NHR 6 , unsubstituted or substituted 5-8 yuan Heteroaryl, unsubstituted or substituted C1-C4 alkyl; wherein, the substitution refers to one or more substituents selected from the following: unsubstituted or substituted with one or more substituents selected from the C group Group substituted C1-C4 alkyl, halogen, hydroxyl, amino, C6-C8 aryl, 5-6 membered heteroaryl, 5-8 membered heterocycloalkyl, C1-C4 alkoxy, C3-C6 ring Alkyl group, C3-C6 cycloalkoxy group, C1-C6 ester group, C1-C4 alkoxycarbonyl group, nitro group, cyano group, C1-C4 alkyl
- the compound of formula (I) is selected from the following specific compounds:
- the compound of the present invention has an asymmetric center, a chiral axis, and a chiral plane, and can exist in the form of racemate, R-isomer, or S-isomer. Those skilled in the art can use conventional technical means to obtain R-isomer and/or S-isomer from racemate resolution.
- the second aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the first aspect, its deuterated compound, stereoisomer, racemate, geometric isomer, and tautomer Isomers, prodrugs, hydrates, solvates or pharmaceutically acceptable salts thereof;
- a pharmaceutically acceptable carrier or excipient is provided.
- the present invention provides novel compounds, which can be used alone or mixed with pharmaceutically acceptable excipients (such as excipients, diluents, etc.) to prepare tablets, capsules, granules or syrups for oral administration, etc. .
- the pharmaceutical composition can be prepared according to conventional methods in pharmacy.
- the third aspect of the present invention provides the compound of the first aspect, its deuterated compound, stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate Or the use of a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to the second aspect, for the preparation of a medicine for the treatment and/or prevention of diseases related to bromodomain protein-mediated; or
- the bromodomain protein-mediated related diseases are selected from cancer, inflammatory diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, acute rejection of transplanted organs, or multiple organ dysfunction Syndrome and Alzheimer's disease.
- deuterated compound in the present invention refers to any hydrogen in the compound in the form of deuterium, and especially includes the following compounds:
- a dash (“-") that is not between two letters or symbols indicates the point of attachment of the substituent.
- C1-C6 alkylcarbonyl- refers to a C1-C6 alkyl group attached to the rest of the molecule through a carbonyl group.
- the attachment point of the substituent is obvious to those skilled in the art, for example, the halogen substituent, "-" can be omitted;
- the wavy line indicates the connection point between the group and other parts of the molecule
- halogen refers to fluorine, chlorine, bromine, and iodine
- alkyl refers to a straight or branched chain alkyl group
- heteroaryl refers to a monocyclic aromatic hydrocarbon group having 5, 6 or 7 ring atoms, such as 6 ring atoms, which contains one or more, such as 1, 2 or 3, in the ring ,
- 6 ring atoms which contains one or more, such as 1, 2 or 3, in the ring ,
- 1 or 2 ring heteroatoms independently selected from N, O and S (e.g. N), the remaining ring atoms are carbon atoms;
- a bicyclic aromatic hydrocarbon group (fused) with 8-12 ring atoms, such as 9 or 10 ring atoms, which contains one or more, such as 1, 2, 3, or 4, such as 1 or 2 ring heteroatoms independently selected from N, O and S, the remaining ring atoms are carbon atoms, and at least one ring is an aromatic ring;
- heterocycloalkyl refers to a heterocycloalkyl (including monocyclic, bridged, spiro ring) containing at least 1 carbon atom and 1-4 heteroatoms selected from O, S, and N, such as 3-12 membered heterocycloalkyl, 3-8 membered heterocycloalkyl, 3-6 membered heterocycloalkyl, etc.; such as oxetanyl, oxetanyl, azetidinyl, ethylene oxide Alkyl, aziridinyl, thietane, 1,2-dithietane, 1,3-dithietane, azepanyl, oxepane Group, 3-azabicyclo[3.1.0]hexyl, 3,6-diazabicyclo[3.1.1]heptyl, 6-azabicyclo[3.1.1]heptyl, 3-azabicyclo[3.1.1]heptyl, 3-azabicyclo[3.1.1]heptyl,
- alkylcarbonyl and “alkylacyl” refer to an alkyl group connected to another group through a carbonyl group, ie, alkyl-C(O)-, where the alkyl group is as defined herein; similar “cycloalkanes” “Hydroxycarbonyl”, “cycloalkylacyl”, “heterocycloalkylcarbonyl” and “heterocycloalkylacyl” are all connected to other groups through a carbonyl group;
- alkoxycarbonyl or “alkoxycarbonyl” as used herein refers to an alkoxy group connected to other groups through a carbonyl group, that is, alkoxy-C(O)-;
- C1-C6 ester group refers to the group C1-C6 alkyl-C(O)-O-, where the alkyl group is as defined above.
- alkylaminoacyl refers to alkyl-NH-C(O)-, such as C1-C6 alkylaminoacyl, ie C1-C6 alkyl-NH-C(O)-;
- alkylamido refers to alkyl-C(O)-NH-, such as C1-C6 alkylamido, ie C1-C6 alkyl-C(O)-NH-;
- C3-C6 cycloalkyloxy or C3-C6 cycloalkoxy as used herein refers to C3-C6 cycloalkyl-O-;
- aryloxy refers to aryl-O-.
- substitution refers to single substitution or multiple substitution, such as two substitution, three substitution, four substitution or five substitution.
- pharmaceutically acceptable salt refers to a non-toxic, biologically tolerable acid addition salt or base addition salt of the compound of formula (I) suitable for administration to an individual, including but not limited to: Acid addition salts formed by compounds of formula (I) with inorganic acids, such as hydrochloride, hydrobromide, carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate, etc.; and I) Acid addition salts formed by compounds and organic acids, such as formate, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate , Methanesulfonate, p-toluenesulfonate, 2-hydroxyethanesulfonate, benzoate, salicylate, stearate and the formula HOOC-(CH 2 ) n -COOH (where n is 0-4) Salts of alkane dicarboxylic acid, etc.
- inorganic acids such as hydrochloride, hydro
- solvates means a solvent addition form that contains stoichiometric or non-stoichiometric solvent. If the solvent is water, the solvate formed is a hydrate, and when the solvent is ethanol, the solvate formed is an ethanolate.
- prodrug refers to an active or inactive compound that is chemically modified into the compound of the invention by in vivo physiological effects such as hydrolysis, metabolism, etc. after being administered to an individual.
- suitable prodrugs are well known to those skilled in the art.
- Exemplary prodrugs are, for example, esters of free carboxylic acids and S-acyl derivatives of thiols and O-acyl derivatives of alcohols or phenols.
- Suitable prodrugs are usually pharmaceutically acceptable ester derivatives that can be converted into the parent carboxylic acid by solvolysis under physiological conditions, such as lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono -Or di-substituted lower alkyl esters, such as ⁇ -(amino, mono- or di-lower alkylamino, carboxyl, lower alkoxycarbonyl)-lower alkyl ester, ⁇ -(lower alkanoyloxy, Lower alkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, such as pivaloyloxymethyl ester, etc., are conventionally used in the art.
- the compounds of the present invention may exist in the form of single stereoisomers (e.g., enantiomers, diastereomers) and mixtures of any ratios such as racemates, and where appropriate, It can exist in the form of its tautomers and geometric isomers.
- stereoisomers refers to compounds that have the same chemical constitution but differ in the arrangement of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformational isomers and the like.
- enantiomers refers to two stereoisomers of a compound that are non-superimposable mirror images of each other.
- diastereomer refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Mixtures of diastereomers can be separated by high-resolution analytical methods such as electrophoresis and chromatography such as HPLC.
- racemic mixture and “racemate” refer to an equimolar mixture of two enantiomers that are not optically active.
- the racemic mixture can be used in its own form or resolved into individual isomers for use. Through resolution, a stereochemically pure compound or a mixture enriched in one or more isomers can be obtained.
- tautomer or "tautomeric form” as used herein refers to structural isomers of different energies that can be converted into each other via a low energy barrier.
- proton tautomers also called proton transfer tautomers
- Valence tautomers include interconversion through the recombination of some bonded electrons.
- geometric isomers refers to isomers caused by double bonds or single bonds of ring carbon atoms that cannot rotate freely. They are also called cis-trans isomers. The substituents on the same side of the plane are cis-forms. The isomer, located on the opposite side of the plane is the trans isomer.
- treatment refers to the administration of one or more drug substances to individuals suffering from a disease or having symptoms of the disease to cure, alleviate, alleviate, change, treat, ameliorate, ameliorate or affect the disease Or the symptoms of the disease.
- prevention refers to the administration of one or more drug substances to individuals who are susceptible to the disease in order to prevent the individual from suffering from the disease.
- the preparation method of the compound of the present invention is selected from the following methods:
- each substituent is as described above; halogen is selected from F, Cl, Br, I; Ar 1 is a C5-C10 aryl group that is unsubstituted or substituted by one or more substituents selected from group B, A 5-8 membered heteroaryl group that is unsubstituted or substituted by one or more substituents selected from group B; R 1a is selected from hydrogen, unsubstituted or halogenated C1-C6 alkoxy, unsubstituted or halogenated C3 -C8 cycloalkyl, C3-C6 cycloalkyloxy, C1-C6 ester group, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 alkylaminoacyl, C1-C6 alkylamide Group, C1-C6 alkyl group unsubstituted or substituted by one or more substituents selected from group A, C5-C10
- the group A substituents include: amino, nitro, cyano, hydroxy, halogen, phenyl, unsubstituted or halogenated C3-C8 cycloalkyl, unsubstituted or halogenated C3-C8 cycloalkoxy;
- the group B substituents include: C1-C4 alkyl, nitro, cyano, fluorine, chlorine, bromine, trifluoromethoxy, hydroxyl, hydroxymethyl, amino, C1-C4 alkoxy, C3-C6 Cycloalkoxy, 4-8 membered heterocycloalkyl that is unsubstituted or substituted by C1-C6 alkyl, C1-C6 ester group, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 alkane Group amino acyl group, C1-C6 alkyl amide group, -SO-(C1-C6 alkyl), -SO 2 -(C1-C6 alkyl).
- the preparation method of the compound of the present invention includes the following steps:
- R 1 is not hydrogen, halogen or not present.
- the preparation method of the compound of the present invention includes the following steps:
- R 1 and R 4 are as defined above;
- R 2 is an unsubstituted or substituted 5-8 membered heteroaryl group; the substitution refers to being substituted by one or more substituents selected from the following: C1-C6 alkyl, halogenated C1-C6 alkyl, halogen, hydroxy, C5-C8 aryl, 5-8 membered heteroaryl, 3-12 membered heterocycloalkyl, C1-C6 alkoxy, C3- C6 cycloalkyl, C3-C6 cycloalkoxy, C1-C6 ester group, C1-C6 alkoxycarbonyl, nitro, cyano, C1-C6 alkyl amide, unsubstituted or selected from group D An amino group substituted by one or more substituents; the D group substituents include: C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkyl amide, and C3
- the compound and pharmaceutical composition of the present invention are used to prepare drugs for treating and/or preventing diseases related to bromodomain protein mediated; or as products for bromodomain protein inhibitors.
- the bromodomain protein-mediated related diseases are selected from cancer, inflammatory diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, acute rejection of transplanted organs, or multiple organ dysfunction Syndrome and Alzheimer's disease.
- the cancer refers to a physiological condition that is typically characterized by unregulated cell growth in mammals.
- the cancer is selected from hematological malignancies, lung cancer, multiple myeloma, neuroblastoma, colon cancer, testicular cancer, and ovarian cancer.
- the cancer is selected from lung cancer (such as small cell lung cancer or non-small cell lung cancer), NUT midline cancer (such as BRD3-NUT midline cancer or BRD4-NUT midline cancer), leukemia, mixed lineage leukemia (MLL), acute myeloid leukemia Cellular leukemia (AML), biphenotype B myelomonocytic leukemia or erythroleukemia.
- the cancer is selected from Burkitt lymphoma, breast cancer, colon cancer, neuroblastoma, glioblastoma multiforme, chronic lymphocytic leukemia and squamous cell carcinoma.
- the inflammatory disease is a disease involving an inflammatory response to infection by bacteria, viruses, fungi, parasites, and/or protozoa.
- the inflammatory disease is selected from osteoarthritis, acute gout, multiple sclerosis, inflammatory bowel disease (such as Crohn’s disease and ulcerative colitis), neuroinflammation, asthma, chronic obstructive airway disease, pneumonia , Myositis, eczema, dermatitis, acne, cellulitis, occlusive disease, thrombosis, alopecia, nephritis, vasculitis, retinitis, uveitis, scleritis, sclerosing cholangitis, hypophysitis, thyroiditis, infection Shock, Systemic Inflammatory Response Syndrome (SIRS), Toxic Shock Syndrome, Acute Lung Injury, ARDS (Adult Respiratory Distress Syndrome), Acute Renal Failure, Burns, Pancreatitis (e.
- the inflammatory disease is acute or chronic pancreatitis.
- the inflammatory disease is burns.
- the inflammatory disease is inflammatory bowel disease.
- the inflammatory disease is neuroinflammation.
- the inflammatory disease is sepsis or sepsis syndrome.
- the inflammatory disease is graft versus host disease (GVHD).
- the cardiovascular disease is selected from the group consisting of atherogenesis, atherosclerosis, stent obstruction, heart failure (e.g. congestive heart failure), coronary artery disease, myocarditis, pericarditis, heart valve disease, stenosis, restenosis, Stent stenosis, angina pectoris, myocardial infarction, acute coronary syndrome, coronary artery bypass graft, cardiopulmonary bypass, endotoxemia, ischemia-reperfusion injury, cerebral ischemia (stroke), renal reperfusion Injury, embolism (such as pulmonary embolism, renal embolism, liver embolism, gastrointestinal embolism or peripheral limb embolism) or myocardial ischemia;
- heart failure e.g. congestive heart failure
- coronary artery disease myocarditis, pericarditis, heart valve disease, stenosis, restenosis, Stent stenosis, angina pectoris, myocardial infarction, acute coronar
- the virus infection is DNA virus infection (such as: dsDNA virus infection, ssDNA virus infection, RNA virus infection and dsRNA virus infection), RNA virus infection, reverse transcription (RT) virus infection, ssRNA-RT virus infection and dsDNART virus infection.
- the viral infection is a human immunodeficiency virus (HIV) infection such as acquired immunodeficiency syndrome (AIDS), human papilloma virus (HPV) infection, hepatitis C virus (HCV) infection, herpes virus infection (e.g. Herpes simplex virus (HSV) infection), Ebola virus infection, severe acute respiratory syndrome (SARS) and influenza virus infection.
- HIV human immunodeficiency virus
- AIDS acquired immunodeficiency syndrome
- HPV human papilloma virus
- HCV hepatitis C virus
- herpes virus infection e.g. Herpes simplex virus (HSV) infection
- Ebola virus infection severe acute respiratory syndrome (SARS) and influenza virus infection.
- the fibrotic disease is selected from renal fibrosis, postoperative stenosis, keloid formation, liver cirrhosis, biliary cirrhosis, cardiac fibrosis, scleroderma, idiopathic pulmonary fibrosis;
- the metabolic disease is selected from endocrine diseases (such as Adison's disease), diabetes (such as type I diabetes, type II diabetes or gestational diabetes), obesity, fatty liver (NASH or other), cachexia, hypercholesterolemia, or undergoing lipid loading A disorder of lipid metabolism regulated by protein A1 (APOA1).
- endocrine diseases such as Adison's disease
- diabetes such as type I diabetes, type II diabetes or gestational diabetes
- obesity fatty liver (NASH or other)
- cachexia hypercholesterolemia
- APOA1 protein A disorder of lipid metabolism regulated by protein A1
- the present invention also provides a method for non-therapeutically inhibiting the activity of bromodomain protein, which method comprises adding an effective amount of the compound represented by formula (I), its deuterated compound, stereoisomer, racemate, geometric Isomers, tautomers, prodrugs, hydrates, solvates or pharmaceutically acceptable salts thereof, or the pharmaceutical composition is contacted with the bromodomain protein, thereby inhibiting the bromodomain protein.
- a method for non-therapeutically inhibiting the activity of bromodomain protein comprises adding an effective amount of the compound represented by formula (I), its deuterated compound, stereoisomer, racemate, geometric Isomers, tautomers, prodrugs, hydrates, solvates or pharmaceutically acceptable salts thereof, or the pharmaceutical composition is contacted with the bromodomain protein, thereby inhibiting the bromodomain protein.
- the 1 H-NMR spectrum is Bluker AVANCE III 400 Hz;
- Step 2 Synthesis of ethyl 7-bromo-5-methyl-4-oxo-4,5-dihydro-2H-pyrrolo[3,4-c]pyridine-1-carboxylate (Intermediate 3)
- Step 3 Synthesis of 7-bromo-5-methyl-2,5-dihydro-4H-pyrrolo[3,4-c]pyridin-4-one (Intermediate 4)
- Step 4 7-Bromo-5-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2,5-dihydro-4H-pyrrolo[3,4- c) Synthesis of pyridin-4-one (Intermediate 5)
- Step 6 7-(hydroxymethyl)-5-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2,5-dihydro-4H-pyrrolo[ Synthesis of 3,4-c]pyridin-4-one (Intermediate 7)
- Step 1 (5-Methyl-4-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-4,5-dihydro-2H-pyrrolo[3, Synthesis of 4-c]pyridine-7-carbaldehyde) (Intermediate 8)
- Step 3 7-benzyl-2,5-dihydro-4H-pyrrolo[3,4-c]pyridin-4-one (A1) and 7-benzyl-5-methyl-2,5-di Synthesis of Hydrogen-4H-pyrrolo[3,4-c]pyridin-4-one (A2)
- A4 sends SFC to split to get A4-P1 (16 mg) and A4-P2 (18 mg)
- A4-P1 LCMS: m/z 308.1 (M-MeO); 1 H-NMR (DMSO, 400MHz): 8.64-8.61 (m, 1H), 8.08 (s, 1H), 7.46-7.44 (m, 2H) ,7.40(s,1H),7.34-7.31(m,2H),7.26-7.24(m,1H),7.08(s,1H),5.21(s,1H),3.38(s,3H),3.32-3.23 (m, 5H), 1.15-1.12 (m, 3H).
- A4-P2 LCMS: m/z 308.1 (M-MeO); 1 H-NMR (DMSO, 400MHz): 8.65-8.62 (m 1H), 8.08 (s, 1H), 7.46-7.44 (m, 2H), 7.40(s, 1H), 7.34-7.31(m, 2H), 7.26-7.22(m, 1H), 7.08(s, 1H), 5.21(s, 1H), 3.38(s, 3H), 3.32-3.23( m, 5H), 1.15-1.12 (m, 3H).
- Step 4 Synthesis of ethyl 3-(5-bromo-1-methyl-3-nitro-2-carbonyl-1,2-dihydropyridin-4-yl)-2-carbonylpropionate (intermediate 18)
- Step 5 Synthesis of 4-bromo-2-(ethoxymethyl)-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (HHX- B38-int)
- Step 1 4-Bromo-N-ethyl-6-methyl-7-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro Synthesis of -1H-pyrrolo[2,3-c]pyridine-2-carboxamide (Intermediate 23)
- Step 2 N-Ethyl-6-methyl-7-oxo-4-(1-phenylvinyl)-1-((2-(trimethylsilyl)ethoxy)methyl) Synthesis of -6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (Intermediate 24)
- Step 3 N-Ethyl-6-methyl-7-oxo-4-(1-phenethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)- Synthesis of 6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (Intermediate 25)
- A5 sends SFC to split to get A5-P1 (4 mg) and A5-P2 (4 mg)
- A6-P1 4.3 mg, a white solid
- A6-P2 4.2 mg, a white solid.
- Step 1 tert-Butyl 4-(6-methyl-7-carbonyl-4-(1-phenylethyl)-6,7-dihydro-1H-pyrrolo[2,3]pyridine-2-carbon Synthesis of weedamido)-1H-pyrazole-1-carboxylate (Intermediate 29)
- Step 3 Synthesis of 3-((tert-butyldimethylsilyl)oxy)-1-(pyridin-2-yl)propan-1-one (Intermediate 33)
- Step 4 3-((tert-butyldimethylsilyl)oxy)-1-(pyridin-2-yl)prop-1-en-1-yltrifluoromethanesulfonic acid (Intermediate 34) synthesis
- Step 5 4-(3-((tert-butyldimethylsilyl)oxy)-1-(pyridin-2-yl)prop-1-en-1-yl)-6-methyl-7 Synthesis of -oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid ethyl ester (Intermediate 35)
- Step 6 4-(3-Hydroxy-1-(pyridin-2-yl)prop-1-en-1-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrole Synthesis of [2,3-c]pyridine-2-carboxylic acid ethyl ester (Intermediate 36)
- Step 7 4-(3-Hydroxy-1-(pyridin-2-yl)propyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c ] Synthesis of ethyl pyridine-2-carboxylate (Intermediate 37)
- Step 8 4-(3-Hydroxy-1-(pyridin-2-yl)propyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c ] Synthesis of pyridine-2-carboxylic acid (Intermediate 38)
- Step 9 N-cyclopropyl-4-(3-hydroxy-1-(pyridin-2-yl)propyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo Synthesis of [2,3-c]pyridine-2-carboxamide (A9)
- Step 4 N-ethyl-4-(hydroxy(phenyl)methyl)-6-methyl-7-oxo-1-((2-(trimethylsilyl)ethoxy)methyl )-6,7-Dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (Intermediate 42)
- Step 5 Synthesis of 4-benzyl-N-ethylamino-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
- Example A12-P1 The spectrum data of Example A12-P1 is as follows: LCMS: m/z 376.2 (M+H).
- Example A12-P2 The spectrum data of Example A12-P2 is as follows: LCMS: m/z 376.1 (M+H).
- 1 H-NMR(DMSO,400MHz): 12.24-12.19(m,1H), 10.26(s,1H), 7.96(s,1H), 7.50(s,1H),7.33-7.26(m,4H), 7.20 -7.15 (m, 2H), 6.82 (s, 1H), 4.22-4.17 (m, 1H), 3.81 (s, 3H), 3.55 (s, 3H), 1.59 (d, J 7.2 Hz, 3H).
- Step 1 Ethyl 6-methyl-4-(1-naphth-2-yl)vinyl)-7-oxo-1-methylbenzenesulfonyl-6,7-dihydro-1H-pyrrolo[ Synthesis of 2,3-c]pyridine-2-carboxylic acid (Intermediate 47)
- Step 2 Ethyl 6-methyl-4-(1-naphth-2-yl)ethyl)-7-oxo-1-p-toluenesulfonyl-6,7-dihydro-1H-pyrrolo[2 ,3-c]Pyridine-2-carboxylic acid synthesis (Intermediate 48)
- Step 1 (E)-2-(5-Bromo-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethylene-1-amine (Intermediate 51)
- Step 3 Synthesis of 1-p-toluenesulfonyl-N-4-bromo-7-methoxy-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine (Intermediate 53)
- intermediate 53 14 g, 0.04 mol
- HBr 70 ml, 40% aqueous solution
- 40 ml ethanol 40 ml ethanol
- Step 5 Synthesis of 4-bromo-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine (Intermediate 55)
- 6-methyl-4-(1-phenylethyl)-1-tosyl-2 could be obtained -(2-(Trifluoromethyl)pyridin-4-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Intermediate 60) 40 mg.
- Step 1 6-Methyl-2-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)-4-(1-phenethyl)-1-tosyl Synthesis of -1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Intermediate 61)
- Step 1 4-(1-(4-Fluorophenyl)vinyl)-6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridine Synthesis of -7-one (Intermediate 63)
- Step 2 4-(1-(4-Fluorophenyl)ethyl)-6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridine Synthesis of -7-one (Intermediate 64)
- TLC monitors the reaction After completion, filter, wash the filter cake with a large amount of ethyl acetate, and spin-dry the filtrate to obtain 4-(1-(4-fluorophenyl)ethyl)-6-methyl-1-p-toluenesulfonyl-1, 6-Dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Intermediate 64) 200 mg.
- Step 3 4-(1-(4-Fluorophenyl)ethyl)-2-iodo-6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo[2,3 -c] Synthesis of pyridine-7-one (Intermediate 65)
- Step 4 4-(1-(4-Fluorophenyl)ethyl)-6-methyl-2-(1H-pyrazol-4-yl)-1-tosyl-1,6-dihydro- Synthesis of 7H-pyrrolo[2,3-c]pyridin-7-one (Intermediate 66)
- Step 5 4-(1-(4-Fluorophenyl)ethyl)-6-methyl-2-(1H-pyrazol-4-yl)-1,6-dihydro-7H-pyrrolo[2 ,3-c) Synthesis of pyridin-7-one (A19)
- Step 1 42-iodo-6-methyl-4-(1-phenethyl)-1H-pyrrole[2,3-c]pyridine-7(6H)-one (Intermediate 67)
- Example A21 was synthesized with the starting material 4-(4,4,5,5-tetramethyl-1,3,2-dioxol-2-yl)-3-methylisoxazole ,
- the structure is as follows:
- Step 1 N-ethyl-6-methyl-4-(1-(naphth-2-yl)vinyl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3- c) Synthesis of pyridine-2-carboxamide (Intermediate 68)
- Step 1 (4-(2,6-Dimethylbenzene)(hydroxy)methyl)-N-ethyl-6-methyl-7-oxo-1-(2-(trimethylsilyl) Synthesis of ethoxy)methyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (Intermediate 69)
- Step 2 4-Formyl-6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid ethyl ester (Intermediate 72)
- Step 3 4-(Hydroxy(phenyl)methyl)-6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine Ethyl-2-carboxylate (Intermediate 74)
- Step 1 4-((4-Hydroxyphenyl)(phenyl)methyl)-6-methyl-7-oxo-1-tolyl-6,7-dihydro-1H-pyrrole [2,3 -c) Ethyl pyridine-2-carboxylate (75) and 4-((2-hydroxyphenyl)(phenyl)methyl)-6-methyl-7-oxo-1-tolyl-6,7 -Dihydro-1H-pyrrole[2,3-c]pyridine-2-ethyl carboxylate (Intermediate 76)
- Step 1 Benzhydryl trimethyl-1,4-azatrifluoromethanesulfonate (Intermediate 78)
- Step 2 4-Benzylmethyl-N-ethylamino-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (A29)
- Step 1 Synthesis of N-(4-fluoro-3,5-dimethylphenyl)-2-nitro-pyridin-3-amine (Intermediate 81)
- Step 2 Synthesis of N-3-(4-fluoro-3,5-dimethylphenyl)pyridine-2,3-diamine (Intermediate 82)
- Step 4 Synthesis of 2-bromo-1-(4-fluoro-3,5-dimethylphenyl)-1H-imidazo[4,5-b]pyridine (Intermediate 84)
- Step 5 N-ethyl-4-(1-(4-fluoro-3,5-dimethylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl)-6-methan Synthesis of phenyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (A30)
- Example A31 The spectrum data of Example A31 is as follows: LCMS: m/z 441.2 (M+H).
- Step 1 Synthesis of 1-cyclopropoxy-4-dinitronaphthalene (Intermediate 87)
- Step 2 Synthesis of 4-cyclopropoxynaphthyl-1-amine (Intermediate 88)
- Step 3 Synthesis of 1-cyclopropoxy-4-iodonaphthalene (Intermediate 89)
- Step 4 Synthesis of methyl 4-cyclopropoxy-1-naphthoate (Intermediate 90)
- Step 5 Synthesis of methyl 3-bromo-4-cyclopropoxy-1-naphthoate (Intermediate 91)
- Step 6 Synthesis of (3-bromo-4-cyclopropylnaphthalen-1-yl)methanol (Intermediate 92)
- Step 7 4-(1-Cyclopropyl-4-(hydroxymethyl)naphthalen-2-yl)-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H- Synthesis of pyrrolo[2,3-c]pyridine-2-carboxamide (A32)
- Step 1 Synthesis of 1-methyl-3-(1-phenylvinyl)-1H-pyrazole (Intermediate 94)
- Step 3 Synthesis of 4-bromo-1-methyl-3-(1-phenylethyl)-1H-pyrazole (Intermediate 96)
- Step 4 N-ethyl-6-methyl-4-(1-methyl-3-(1-phenylethyl)-1H-pyrazol-4-yl)-7-oxo-6,7 Synthesis of -Dihydro-1H-pyrrolo[2,3c]pyridine-2-carboxamide (A33)
- Step 5 4-(3,5-Dicyclopropyl-1-methyl-1H-pyrazol-4-yl)-N-ethyl-6-methyl-7-oxo-6,7-di Synthesis of Hydrogen-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (A34)
- Step 1 Synthesis of 1-(1-phenylethyl)-1H-pyrazole-4-carboxylic acid ethyl ester (Intermediate 103)
- Step 2 Synthesis of 5-bromo-1-(1-phenylethyl)-1H-pyrazole-4-carboxylic acid ethyl ester (Intermediate 104)
- Step 4 Synthesis of 5-bromo-N-ethyl-1-(1-phenylethyl)-1H-pyrazole-4-carboxamide (Intermediate 106)
- Step 5 N-Ethyl-4-(4-(ethylcarbamoyl)-1-(1-phenylethyl)-1H-pyrazol-5-yl)-6-methyl-7-oxy Synthesis of Subo-6,7-Dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (A35)
- Step 5 N-Ethyl-4-(4-(hydroxymethyl)-1-(p-tolyl)-1H-imidazol-2-yl)-6-methyl-7-oxo-6,7- Synthesis of Dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (A36)
- Step 4 Synthesis of 5-iodo-8-cyclopropoxy-quinoline (Intermediate 117)
- Step 5 Synthesis of 5-carboxylic acid methyl ester-8-cyclopropoxyquinoline (Intermediate 118)
- Step 7 Synthesis of methyl 7-bromo-8-methoxyquinoline-5-carboxylate (Intermediate 120)
- Step 8 Synthesis of 1-(7-bromo-8-methoxyquinolin-5-yl)ethan-1-one (Intermediate 121)
- Step 1 4-(Hydroxy(1-methyl-1H-indol-5-yl)methyl)-6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H -Synthesis of Pyrrolo[2,3-c]pyridine-2-carboxylic acid (Intermediate 123)
- Step 2 N-Ethyl-4-(hydroxy(1-methyl-1H-indol-5-yl)methyl)-6-methyl-7-oxo-6,7-dihydro-1H- Pyrrolo[2,3-c]pyridine-2-carboxamide (A39)
- Step 1 Synthesis of 2-(7-bromo-8-methylquinolin-5-yl)propan-2-ol (Intermediate 124)
- Step 2 1-Methyl-3-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyridine Synthesis of azole (Intermediate 127)
- Step 5 Synthesis of 2-bromo-5-methyl-7-(1-phenylethyl)thieno[3,2-c]pyridine-4(5H)-one (Intermediate 133)
- reaction system was cooled to room temperature and diluted with water, extracted with ethyl acetate, the organic phase was washed with water and saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the residue was concentrated with prep-TLC (ethyl acetate Ester) was purified to obtain product A40 (55 mg, yellow solid), yield: 27%.
- Step 1 6-Methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxylic acid methyl ester (Intermediate 134)
- Step 2 4-(Hydroxymethyl)-6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
- Step 3 6-Methyl-7-oxo-1-p-toluenesulfonyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carbaldehyde
- Step 4 4-(Hydroxy(phenyl)methyl)-6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one Synthesis of (Intermediate 137)
- Step 5 4-(Methoxy(phenyl)methyl)-6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridine-7 -Synthesis of Ketone (Intermediate 138)
- Step 6 2-Iodo-4-(methoxy(phenyl)methyl)-6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo[2,3-c ]Pyridin-7-one(139)
- Step 7 4-(Methoxy(phenyl)methyl)-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)-1-tosyl-1,6- Dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Intermediate 140)
- Step 8 4-(Methoxy(phenyl)methyl)-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)-1,6-dihydro-7H-pyrrole And [2,3-c]pyridin-7-one (Example A43)
- Example A44 was synthesized using a synthesis method similar to A43 (yield: 93%).
- A46 sends SFC to split to get A46-P1 and A46-P2, the data is as follows:
- Step 1 Synthesis of methyl 4-oxo-4-(p-tolyl)butyrate (Intermediate 142)
- Step 2 Synthesis of 5-(p-tolyl)pyrrolidin-2-one (Intermediate 143)
- Step 1 4-Bromo-6-methyl-2-(1H-pyrazol-4-yl)-1-tosyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridine Synthesis of -7-one (Intermediate 144)
- Step 1 6-Methyl-2-(1-methyl-1H-pyrazol-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxboron Synthesis of cyclopentane-2-yl)-1-tosyl 1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (146)
- Step 2 Intermediate 148: 4-(1-(3,5-Dimethylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl)-6-methyl-2-( 1-Methyl-1H-pyrazol-4-yl)-1-tosyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Intermediate 148) synthesis
- Step 3 4-(1-(3,5-Dimethylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl)-6-methyl-2-(1-methyl Synthesis of -1H-pyrazol-4-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (A49)
- Example A49 The data of Example A49 is as follows: LCMS: m/z 450.2 (M+H).
- the compound A54-P1 and compound A54-P2 were obtained by chiral resolution using the synthetic method of SFC.
- the data are as follows:
- Step 1 Synthesis of 3-hydroxy-3-(p-tolyl)isoindolin-1-one (Intermediate 150)
- the compound isoindoline-1,3-dione (2.0 g, 13.6 mmol) was added to a 50 ml three-necked round bottom flask containing 20 ml of dichloromethane, the system was reduced to zero degrees Celsius, and added dropwise under the protection of nitrogen. P-phenylmagnesium bromide (1 mol/L, 41 mL, 40.8 mmol) was added and reacted at room temperature overnight.
- intermediate 151 was used instead of intermediate 143 to synthesize compound A55.
- Step 5 6-Methyl-4-(1-methyl-4-(p-tolyl)-1H-pyrazol-3-yl)-7-oxo-1-tosyl-6,7-di Synthesis of Hydrogen-1H-pyrrolidinyl[2,3]-c]pyridine-2-carboxylic acid ethyl ester (Intermediate 157)
- Step 7 6-Methyl-4-(1-methyl-4-(p-tolyl)-1H-pyrazol-3-yl)-7-oxo-N-(1H-pyrazol-4-yl) )-6,7-Dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (A56)
- Step 5 Synthesis of 2-bromo-5-methyl-7-(1-phenylethyl)furo[3,2-c]pyridine-4(5H)-one (Intermediate 164)
Abstract
Description
Top mirror | LANCE/DELFIA Dual/Bias(446) |
Exc.Filter | UV2(TRF)320 |
Ems.Filter | APC 665 |
2 nd Ems.Filter | Europium 615 |
Claims (11)
- 式(I)化合物、其氘代化合物、立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐:其中,环A为五元杂芳环,X 1、X 2和X 3各自独立地选自C、N、O和S且不同时为C;优选地,X 1、X 2和X 3中一个为N,另两个为C;R 3、R 2、R 4分别为X 1、X 2和X 3上的取代基或不存在;R 1和R 4中一个为氢、卤素或不存在,另一个选自无取代或取代的C1-C6烷基,无取代或取代的C2-C6烯基,无取代或取代的C3-C6环烷基,无取代或取代的4-8元杂环烷基,无取代或取代的5-12元芳基氧基,无取代或取代的氨基,无取代或取代的5-12元杂芳基,无取代或取代的萘基,无取代或取代的C1-C6烷基氨基酰基,无取代或取代的C1-C6烷基酰胺基;其中,所述取代是指被选自如下的一个或多个取代基所取代:=O、羟基,卤素,无取代或卤代C1-C6烷氧基,无取代或卤代C3-C8环烷基,C3-C6环烷基氧基,C1-C6酯基,C1-C6烷氧基羰基,C1-C6烷基羰基,C1-C6烷基氨基酰基,C1-C6烷基酰胺基,无取代或被选自A组的一个或多个取代基所取代的C1-C6烷基,无取代或被选自B组的一个或多个取代基所取代的C5-C10芳基,无取代或被选自B组的一个或多个取代基所取代的5-8元杂芳基,无取代或被选自B组的一个或多个取代基所取代的4-8元杂环烷基酰基,无取代或被选自B组的一个或多个取代基所取代的C5-C8芳氧基;所述A组取代基包括:氨基、硝基、氰基、羟基、卤素、苯基、无取代或卤代的C3-C8环烷基、无取代或卤代的C3-C6环烷氧基;所述B组取代基包括:C1-C6烷基、硝基、氰基、卤素、卤代C1-C6烷基、羟基、羟甲基、氨基、无取代或卤代C1-C6烷氧基、C3-C6环烷氧基、无取代或被C1-C6烷基取代的3-8元杂环烷基、C1-C6酯基、C1-C6烷氧基羰基、C1-C6烷基羰基、C1-C6烷基氨基酰基,C1-C6烷基酰胺基、-SO-(C1-C6烷基)、-SO 2-(C1-C6烷基);R 2选自H、-COO-R 6,-CO-NH-R 6,-NH-CO-R 6,-SO 2-NHR 6,无取代或取代的5-8元杂芳基,无取代或取代的C1-C6烷基;其中,所述取代是指被选自如下的一个或多个取代基所取代:无取代或被选自C组的一个或多个取代基所取代的C1-C6烷基、卤素、羟基、C5-C8芳基、5-8元杂芳基、3-12元杂环烷基、C1-C6烷氧基、C3-C6环烷基、C3-C6环烷氧基、C1-C6酯基、C1-C6烷氧基羰基、硝基、氰基、C1-C6烷基酰胺基、无取代或被选自D组的一个或多个取代基所取代的氨基;所述C组取代基包括:卤素、羟基、C3-C6环烷基、3-12元杂环烷基、C1-C6烷基取代的3-12元杂环烷基;所述D组取代基 包括:C1-C6烷基、卤代C1-C6烷基、C1-C6烷基酰胺基、C3-C6环烷基;R 6选自无取代或被卤素取代的C1-C6烷基,无取代或被卤素取代的C3-C6环烷基,无取代或被C1-C6烷基取代的5-8元杂芳基,无取代或被C1-C6烷基取代的5-8元杂环烷基;R 3为C1-C6烷基,卤素,无取代或被氨基保护基取代的氨基,C1-C6烷基酰胺基,硝基,氰基,羧基或氢,优选为氢;且式(I)化合物不为以下化合物:
- 如权利要求1所述的化合物、其氘代化合物、立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐,其特征在于,环A为五元杂芳环,X 1、X 2和X 3各自独立地选自C、N、O和S且不同时为C;优选地,X 1、X 2和X 3中一个为N,另两个为C;R 3、R 2、R 4分别为X 1、X 2和X 3上的取代基或不存在;R 1和R 4中一个为氢、卤素或不存在,另一个选自无取代或取代的C1-C6烷基,无取代或取代的C2-C6烯基,无取代或取代的C3-C6环烷基,无取代或取代的4-8元杂环烷基,无取代或取代的5-12元芳基氧基,无取代或取代的氨基,无取代或取代的5-12元杂芳基,无取代或取代的萘基,无取代或取代的C1-C6烷基氨基酰基,无取代或取代的C1-C6烷基酰胺基;其中,所述取代是指被选自如下的一个或多个取代基所取代:=O、羟基,卤素,无取代或卤代C1-C6烷氧基,无取代或卤代C3-C8环烷基,C3-C6环烷基氧基,C1-C6酯基,C1-C6烷氧基羰基,C1-C6烷基羰基,C1-C6烷基氨基酰基,C1-C6烷基酰胺基,无取代或被选自A组的一个或多个取代基所取代的C1-C6烷基,无取代或被选自B组的一个或多个取代基所取代的C5-C10芳基,无取代或被选自B组的一个或多个取代基所取代的5-8元杂芳基,无取代或被选自B组的一个或多个取代基所取代的4-8元杂环烷基酰基,无取代或被选自B组的一个或多个取代基所取代的C5-C8芳氧基;所述A组取代基包括:氨基、硝基、氰基、羟基、卤素、苯基、无取代或卤代的C3-C8环烷基、无取代或卤代的C3-C6环烷氧基;所述B组取代基包括:C1-C6烷基、硝基、氰基、卤素、卤代C1-C6烷基、羟基、羟甲基、氨基、无取代或卤代C1-C6烷氧基、C3-C6环烷氧基、无取代或被C1-C6烷基取代的3-8元杂环烷基、C1-C6酯基、C1-C6烷氧基羰基、C1-C6烷基羰基、C1-C6烷基氨基酰基,C1-C6烷基酰胺基、-SO-(C1-C6烷基)、-SO 2-(C1-C6烷基);R 2选自H、-COO-R 6,-CO-NH-R 6,-NH-CO-R 6,-SO 2-NHR 6,无取代或取代的5-8元杂芳基,无取代或取代的C1-C6烷基;其中,所述取代是指被选自如下的一个或多 个取代基所取代:C1-C6烷基、卤代C1-C6烷基、卤素、羟基、C5-C8芳基、5-8元杂芳基、3-12元杂环烷基、C1-C6烷氧基、C3-C6环烷基、C3-C6环烷氧基、C1-C6酯基、C1-C6烷氧基羰基、硝基、氰基、C1-C6烷基酰胺基、无取代或被选自D组的一个或多个取代基所取代的氨基;所述D组取代基包括:C1-C6烷基、卤代C1-C6烷基、C1-C6烷基酰胺基、C3-C6环烷基;R 6选自无取代或被卤素取代的C1-C6烷基,无取代或被卤素取代的C3-C6环烷基,无取代或被C1-C6烷基取代的5-8元杂芳基,无取代或被C1-C6烷基取代的5-8元杂环烷基;R 3为C1-C6烷基,卤素,氨基,C1-C6烷基酰胺基,硝基,氰基或氢,优选为氢。
- 如权利要求1或2所述的化合物、其氘代化合物、立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐,其特征在于,R 1和R 4中一个为氢或不存在,另一个选自取代的C1-C4烷基,取代的C2-C4烯基,无取代或取代的C3-C6环烷基,无取代或取代的含N的5元杂环烷基,无取代或取代的氨基,无取代或取代的含N的5-10元杂芳基,无取代或取代的萘基,无取代或取代的C1-C6烷基氨基酰基;其中,所述取代是指被选自如下的一个或多个取代基所取代:=O,羟基,卤素,C1-C4烷氧基,C3-C6环烷基,C3-C6环烷基-O-,C1-C6酯基,C1-C4烷氧基羰基,C1-C4烷基羰基,C1-C4烷基氨基酰基,C1-C4烷基酰胺基,无取代或被选自A组的一个或多个取代基所取代的C1-C4烷基,无取代或被选自B组一个或多个的取代基所取代的C5-C10芳基,无取代或被选自B组的一个或多个取代基所取代的5-8元杂芳基,无取代或被选自B组的一个或多个取代基所取代的4-6元杂环烷基酰基,无取代或被选自B组 的一个或多个取代基所取代的C6-C8芳氧基;当R 1或R 4为取代的C1-C4烷基或取代的C2-C4烯基时,所述取代是指被选自如下的一个或多个取代基所取代:卤素、羟基、C1-C4烷氧基、无取代或被选自B组一个或多个的取代基所取代的C5-C10芳基,无取代或被选自B组的一个或多个取代基所取代的5-8元杂芳基,无取代或被选自B组的一个或多个取代基所取代的C6-C8芳氧基;所述A组取代基包括:氨基、硝基、氰基、羟基、卤素、苯基、无取代或卤代的C3-C8环烷基、无取代或卤代的C3-C8环烷氧基;所述B组取代基包括:C1-C4烷基、硝基、氰基、氟、氯、溴、三氟甲氧基、羟基、羟甲基、氨基、C1-C4烷氧基、C3-C6环烷氧基、无取代或被C1-C6烷基取代的4-8元杂环烷基、C1-C6酯基、C1-C6烷氧基羰基、C1-C6烷基羰基、C1-C6烷基氨基酰基,C1-C6烷基酰胺基、-SO-(C1-C6烷基)、-SO 2-(C1-C6烷基)。
- 如权利要求1或2所述的化合物、其氘代化合物、立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐,其特征在于,R 1和R 4中一个为氢、卤素或不存在,另一个选自:其中,Y 1、Y 2和Y 3分别选自C和N且不同时为氮;R 7选自氢、无取代或卤代的C1-C5烷基、无取代或卤代的C3-C8环烷基、羟基、羟基取代的C1-C4烷基、甲氧基、卤素、苯基、苯甲基、苯氧基、三氟甲基取代的苯氧基、三氟甲氧基、三氟甲氧基取代的苯氧基、5-8元杂芳基、3-8元杂环烷基;R 8为所在苯基或六元杂芳基上的取代基,m为取代基R 8的个数,m选自0~4的整数(m优选为0,1,2);当m≥2时,R 8相同或不同;R 8所代表的取代基各自独立地选自:氢、C1-C6烷基、硝基、氰基、卤素、三氟甲氧基、羟基、羟甲基、氨基、C1-C6烷氧 基、C3-C6环烷氧基、无取代或被C1-C6烷基取代的3-8元杂环烷基;R 9为所在萘基上的取代基,n为取代基R 9的个数,n选自0~4的整数(n优选为0,1,2);当n≥2时,R 9相同或不同;R 9所代表的取代基各自独立地选自:C1-C6烷基、硝基、氰基、卤素、三氟甲氧基、羟基、羟甲基、氨基、C1-C6烷氧基、C3-C6环烷氧基、无取代或被C1-C6烷基取代的4-8元杂环烷基;R 10为所在苯基上的取代基,j为取代基R 10的个数,j选自0~4的整数(j优选为0,1,2);当j≥2时,R 10相同或不同;R 10所代表的取代基各自独立地选自:C1-C6烷基、硝基、氰基、卤素、三氟甲氧基、羟基、羟甲基、氨基、C1-C6烷氧基、C3-C6环烷氧基;R 11选自氢或C1-C6烷基;R 12、R 13各自独立地选自氢、C1-C6烷基、C3-C6环烷基、C3-C6环烷氧基、C1-C6烷基羰基、C1-C6烷氧基、氨基、羟基、羟基取代的C1-C6烷基;R 14选自C1-C6烷基、C1-C6酯基、C1-C6烷氧基羰基、C1-C6烷基氨基酰基、C1-C6烷基酰胺基;R 15、R 16、R 17各自独立地选自氢、C1-C6烷基、苯基取代的C1-C6烷基、C3-C6环烷基、环己基取代的C1-C6烷基、苯基、C1-C6烷基取代的苯基、羟基、羟甲基、羟乙基、三氟甲氧基、C1-C6烷氧基、C1-C6烷基羰基、C1-C6酯基、C1-C6烷氧基羰基、C1-C6烷基氨基酰基、C1-C6烷基酰胺基、苯氧基;R 18选自氢、C1-C6烷基、羟基;R 19选自无取代或被选自卤素、无取代或卤代C1-C6烷基、无取代或卤代C1-C6烷氧基、羟基、-SO-(C1-C6烷基)、-SO 2-(C1-C6烷基)中的一种或多种取代的苯基。
- 如权利要求1或2所述的化合物、其氘代化合物、立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐,其特征在于,R 2选自H、-COO-R 6,-CO-NH-R 6,-NH-CO-R 6,-SO 2-NHR 6,无取代或取代的5-8元杂芳基,无取代或取代的C1-C4烷基;其中,所述取代是指被选自如下的一个或多个取代基所取代:无取代或被选自C组的一个或多个取代基所取代的C1-C4烷基、卤素、羟基、氨基、C6-C8芳基、5-6元杂芳基、5-8元杂环烷基、C1-C4烷氧基、C3-C6环烷基、C3-C6环烷氧基、C1-C6酯基、C1-C4烷氧基羰基、硝基、氰基、C1-C4烷基酰胺基;R 6选自无取代或被卤素取代的C1-C4烷基,无取代或被卤素取代的C3-C6环烷基,无取代或被C1-C6烷基取代的5-6元杂芳基,无取代或被C1-C6烷基取代的5-6元杂环烷基;所述C组取代基包括:卤素、羟基、4-6元杂环烷基、C1-C4烷基取代的4-6元杂环烷基。
- 一种药物组合物,其特征在于,包含:如权利要求1或2所述的式(I)所示化合物、其氘代化合物、立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐;和药学上可接受的载体。
- 如权利要求1或2所述的化合物、其氘代化合物、立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐,或权利要求9所述的药物组合物的用途,其特征在于,用于制备用于治疗和/或预防与溴结构域蛋白介导相关的疾病的药物;或用作溴结构域蛋白抑制剂的产品。
- 如权利要求10所述的用途,其特征在于,所述溴结构域蛋白介导相关的疾病选自:癌症、炎症疾病、心血管疾病、病毒感染、纤维化疾病、代谢疾病、移植器官的急性排斥或多器官功能障碍综合征和阿尔茨海默氏病。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20874532.3A EP4043462A4 (en) | 2019-10-08 | 2020-09-24 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF |
JP2022520955A JP7405468B2 (ja) | 2019-10-08 | 2020-09-24 | Brd4阻害活性を有する化合物、その調製方法および用途 |
CN202080062423.XA CN114401964A (zh) | 2019-10-08 | 2020-09-24 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
IL291947A IL291947A (en) | 2019-10-08 | 2020-09-24 | A compound with bromodomain-containing protein 4 (brd4) inhibitory activity, methods for its preparation and its uses |
AU2020362763A AU2020362763B2 (en) | 2019-10-08 | 2020-09-24 | Compound having BRD4 inhibitory activity, preparation method therefor and use thereof |
KR1020227014561A KR20220110175A (ko) | 2019-10-08 | 2020-09-24 | Brd4 억제 활성을 갖는 화합물, 이의 제조 방법 및 용도 |
CA3156547A CA3156547A1 (en) | 2019-10-08 | 2020-09-24 | COMPOUND HAVING A BRD4 INHIBITOR ACTIVITY, METHOD FOR PREPARING IT AND ITS USE |
US17/766,601 US20240150343A1 (en) | 2019-10-08 | 2020-09-24 | Compound having brd4 inhibitory activity, preparation method therefor and use thereof |
MX2022004143A MX2022004143A (es) | 2019-10-08 | 2020-09-24 | Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910951369.3 | 2019-10-08 | ||
CN201910951369.3A CN112625036A (zh) | 2019-10-08 | 2019-10-08 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021068755A1 true WO2021068755A1 (zh) | 2021-04-15 |
Family
ID=75283242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/117478 WO2021068755A1 (zh) | 2019-10-08 | 2020-09-24 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240150343A1 (zh) |
EP (1) | EP4043462A4 (zh) |
JP (1) | JP7405468B2 (zh) |
KR (1) | KR20220110175A (zh) |
CN (2) | CN112625036A (zh) |
AU (1) | AU2020362763B2 (zh) |
CA (1) | CA3156547A1 (zh) |
IL (1) | IL291947A (zh) |
MX (1) | MX2022004143A (zh) |
TW (1) | TW202115061A (zh) |
WO (1) | WO2021068755A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113402515A (zh) * | 2021-05-12 | 2021-09-17 | 四川大学华西医院 | 一种吲哚类化合物及其制备方法和用途 |
WO2022012456A1 (en) * | 2020-07-17 | 2022-01-20 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Novel heterocyclic compounds as bet inhibitors |
WO2023275542A1 (en) | 2021-06-29 | 2023-01-05 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113121531B (zh) * | 2021-04-20 | 2023-06-13 | 上海药明康德新药开发有限公司 | N杂吲哚类化合物、其合成方法和医药上的用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015081246A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081189A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081203A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2016077380A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Substituted pyrrolopyridines as inhibitors of bromodomain |
WO2017177955A1 (en) | 2016-04-15 | 2017-10-19 | Abbvie Inc. | Bromodomain inhibitors |
WO2018188047A1 (en) | 2017-04-14 | 2018-10-18 | Abbvie Inc. | Bromodomain inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
US9085578B2 (en) | 2012-02-20 | 2015-07-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2014078257A1 (en) | 2012-11-14 | 2014-05-22 | Glaxosmithkline Llc | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
WO2014125408A2 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
US9670221B2 (en) | 2013-03-14 | 2017-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Furopyridines as bromodomain inhibitors |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
RU2016102647A (ru) | 2013-06-28 | 2017-08-01 | Эббви Инк. | Ингибиторы бромодомена |
PL3640241T3 (pl) * | 2013-10-18 | 2022-12-05 | Celgene Quanticel Research, Inc. | Inhibitory bromodomeny |
NZ763740A (en) | 2014-04-23 | 2023-06-30 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
JP6639497B2 (ja) | 2014-11-10 | 2020-02-05 | ジェネンテック, インコーポレイテッド | ブロモドメインインヒビターおよびその使用 |
WO2016123391A1 (en) * | 2015-01-29 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
CN108069958A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
TW201825490A (zh) * | 2017-01-11 | 2018-07-16 | 大陸商江蘇豪森藥業集團有限公司 | 吡咯並[2,3-c]吡啶類衍生物、其製備方法及其在醫藥上的應用 |
EP3630775B1 (en) * | 2017-05-31 | 2022-12-14 | ChemoCentryx, Inc. | 6-5 FUSED RINGS AS C5a INHIBITORS |
CN110769822A (zh) * | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
JP2021506903A (ja) * | 2017-12-20 | 2021-02-22 | 貝達薬業股▲ふん▼有限公司Betta Pharmaceuticals Co.,Ltd | ブロモドメインタンパク質阻害剤である化合物、および組成物 |
WO2019152440A1 (en) * | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Methods and compounds for treating disorders |
WO2019151269A1 (ja) | 2018-01-31 | 2019-08-08 | 武田薬品工業株式会社 | 複素環化合物 |
EP3749672B1 (en) | 2018-02-06 | 2022-07-27 | Ontario Institute for Cancer Research (OICR) | Inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof |
CN110305123B (zh) * | 2018-03-27 | 2021-12-10 | 海创药业股份有限公司 | 一种含有金刚烷的化合物及其在治疗癌症中的用途 |
GB201905721D0 (en) * | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
-
2019
- 2019-10-08 CN CN201910951369.3A patent/CN112625036A/zh active Pending
-
2020
- 2020-09-23 TW TW109132842A patent/TW202115061A/zh unknown
- 2020-09-24 AU AU2020362763A patent/AU2020362763B2/en active Active
- 2020-09-24 WO PCT/CN2020/117478 patent/WO2021068755A1/zh active Application Filing
- 2020-09-24 CA CA3156547A patent/CA3156547A1/en active Pending
- 2020-09-24 US US17/766,601 patent/US20240150343A1/en active Pending
- 2020-09-24 IL IL291947A patent/IL291947A/en unknown
- 2020-09-24 MX MX2022004143A patent/MX2022004143A/es unknown
- 2020-09-24 JP JP2022520955A patent/JP7405468B2/ja active Active
- 2020-09-24 KR KR1020227014561A patent/KR20220110175A/ko not_active Application Discontinuation
- 2020-09-24 CN CN202080062423.XA patent/CN114401964A/zh active Pending
- 2020-09-24 EP EP20874532.3A patent/EP4043462A4/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015081246A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081189A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081203A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2016077380A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Substituted pyrrolopyridines as inhibitors of bromodomain |
WO2017177955A1 (en) | 2016-04-15 | 2017-10-19 | Abbvie Inc. | Bromodomain inhibitors |
CN109071534A (zh) * | 2016-04-15 | 2018-12-21 | 艾伯维公司 | 布罗莫结构域抑制剂 |
WO2018188047A1 (en) | 2017-04-14 | 2018-10-18 | Abbvie Inc. | Bromodomain inhibitors |
Non-Patent Citations (3)
Title |
---|
LANGONE MEDICAL CENTER, 2014 |
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP4043462A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022012456A1 (en) * | 2020-07-17 | 2022-01-20 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Novel heterocyclic compounds as bet inhibitors |
CN115667237A (zh) * | 2020-07-17 | 2023-01-31 | 成都苑东生物制药股份有限公司 | 作为bet抑制剂的新型杂环化合物 |
CN113402515A (zh) * | 2021-05-12 | 2021-09-17 | 四川大学华西医院 | 一种吲哚类化合物及其制备方法和用途 |
CN113402515B (zh) * | 2021-05-12 | 2022-05-27 | 四川大学华西医院 | 一种吲哚类化合物及其制备方法和用途 |
WO2023275542A1 (en) | 2021-06-29 | 2023-01-05 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
GB2621505A (en) * | 2021-06-29 | 2024-02-14 | Tay Therapeutics Ltd | Pyrrolopyridone derivatives useful in the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
CN112625036A (zh) | 2021-04-09 |
JP2022551299A (ja) | 2022-12-08 |
MX2022004143A (es) | 2022-07-21 |
EP4043462A1 (en) | 2022-08-17 |
IL291947A (en) | 2022-06-01 |
CN114401964A (zh) | 2022-04-26 |
TW202115061A (zh) | 2021-04-16 |
JP7405468B2 (ja) | 2023-12-26 |
US20240150343A1 (en) | 2024-05-09 |
AU2020362763A1 (en) | 2022-04-28 |
KR20220110175A (ko) | 2022-08-05 |
EP4043462A4 (en) | 2023-11-01 |
CA3156547A1 (en) | 2021-04-15 |
AU2020362763B2 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2485731B1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
JP5989805B2 (ja) | メチル基変更酵素の調節物質、組成物及びその使用 | |
JP7405468B2 (ja) | Brd4阻害活性を有する化合物、その調製方法および用途 | |
KR101943680B1 (ko) | 피라졸로퀴놀린 유도체 | |
CN104837829B (zh) | 抑制剂化合物 | |
TW202214605A (zh) | 免疫調節劑、組合物及其方法 | |
BR112020026545A2 (pt) | Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington | |
JP2018150358A (ja) | Tank結合キナーゼインヒビター化合物 | |
CN114144230B (zh) | 作为eed和prc2调节剂的大环唑并吡啶衍生物 | |
AU2022200478B2 (en) | Inhibitors of KEAP1-Nrf2 protein-protein interaction | |
CA2954976A1 (en) | Spirocycloheptanes as inhibitors of rock | |
KR20160056896A (ko) | Pim 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물 | |
CA3085460A1 (en) | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
TWI508968B (zh) | 用於治療呼吸道融合性病毒感染的化合物 | |
CA3185649A1 (en) | Indole compounds as androgen receptor modulators | |
KR102351782B1 (ko) | 피리도 5원 방향족 고리계 화합물, 이의 제조 방법 및 용도 | |
CN112028877B (zh) | 烷氧吡啶酮化合物及其制备方法和用途 | |
CN110407854B (zh) | 新的四环化合物 | |
KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 | |
EP4313308A1 (en) | Tead inhibitors and uses thereof | |
CN116635028A (zh) | c-MYC mRNA翻译调节剂及其在治疗癌症中的用途 | |
TW202214634A (zh) | 雜環化合物及其衍生物 | |
CN116981458A (zh) | 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20874532 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3156547 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022520955 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17766601 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022006501 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020362763 Country of ref document: AU Date of ref document: 20200924 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020874532 Country of ref document: EP Effective date: 20220509 |
|
ENP | Entry into the national phase |
Ref document number: 112022006501 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220404 |